

Description

Title of Invention : 2,4,5-Tri-substituted Azole-Based Casein Kinase 1 Inhibitors as Inducers for Cardiomyogenesis

Technical Field

The present invention generally relates to the method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocytes via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor which is a 2,4,5-tri-substituted azole compound. The present invention also relates to new 2,4,5-tri-substituted azoles and the use of 2,4,5-tri-substituted azoles in the above methods.

Background Art

In regenerative medicine significant progress has been made in stem cell therapy. Heart diseases which are associated with the degeneration of cardiomyocytes may be treated via the use of stem cells. Such stem cells, especially human embryonic stem cells (hESCs), need to be differentiated into cardiomyocytes. For such differentiation the use of small molecules has been found to be a particularly advantageous way to support the differentiation process. Such small molecules can be synthesized easily, are reversible with respect to effect on cells, and can be administered temporarily. One suitable molecule that has been reported is SB203580 (cf. WO2013056072 A1, US20130189785) which is used as a p38 α MAPK inhibitor in the differentiation pathway.

It has been further found that a preferred method to generate cardiomyocytes is to inhibit the canonical Wnt pathway at certain time points during the differentiation process. Although there are many potent inhibitors which can inhibit parts of the Wnt pathway, research thus far indicates that only inhibition of porceine and tankyrase within the canonical Wnt pathway was effective in generating cardiomyocytes. This limits the number of suitable small molecules which can be utilized for cardiomyocyte differentiation.


Furthermore there is a need for more efficient methods to generate cardiomyocytes via the embryonic body (EB) suspension culture method which can be scaled in bioreactors for future stem cells therapy, research and pharmacological drug testing. All applications demand cardiomyocytes of high quality (i.e. functionality based on parameters such as beat count, beating area, and beating frequency) and in high quantity. There is still a need to overcome difficulties associated with low efficiency (<10%) and the poor yields of conventional cardiomyocyte differentiation protocols via EBs.

There is therefore a need to address the Wnt pathway in a different way utilizing other time points and/or new small molecules to provide a method that overcomes, or at least ameliorates, one or more of the disadvantages described above.


Summary

According to the disclosure, there is provided a method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof:

[Formula (I)]



[Formula (II)]




wherein R^1 , R^2 and R^3 independently from another represent hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl;

X represents NR^4 , O or S; and


R^4 represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl.

According to a first aspect, there is provided a method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof

[Formula (I)]



[Formula (II)]



wherein R^1 represents fluorine substituted aryl having 6 to 10 carbon atoms, wherein the aryl is optionally additionally substituted by one or more substituents;

R^2 represents fluorine substituted phenyl, wherein the phenyl is optionally additionally substituted by one or more substituents;

R^3 represents pyridinyl or pyranlyl; and


X represents NH.

Advantageously the use of small molecules that inhibit Wnt pathway during cardiomyocyte differentiation of pluripotent stem cells via casein kinase 1 (CK1 or CK 1) inhibition leads to improved differentiation. Differentiation of cardiomyocytes via inhibition of CK1 can be used on human induced pluripotent stem cells and human embryonic stem cells after EB formation, preferably from day 2 onwards. The small molecules according to the invention target CK 1 epsilon and CK 1 delta to give 10-20 % cardiomyocytes when applied as the sole inhibitor which is significantly better compared to other inhibition pathway methods. In the method of the invention not only the Wnt pathway, but also the stress pathway, is addressed. This double inhibition of Wnt and cell stress pathways according to the inventive method is unique. Wnt pathway inhibition is known to inhibit growth in cells. Many protocols compensate for this effect with highly expensive differentiation medium supplements (e.g. B27) that provides

several growth factors to compensate for growth inhibition and boost cell growth. Such compensation is not needed with the use of selected small molecules according to the inventive method.

According to the present disclosure, the compounds of formula (I), (Ia), (Ia)' and (II), especially IM-31 and ZQX-19, can therefore be used in methods to promote cell growth and survival.

According to another aspect, there is provided a method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (Ia) or a stereoisomer, tautomer, or a salt thereof



(Ia)

wherein B, B¹, Y¹ and Z¹ are absent or each independently selected from C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, thio-C₁-C₆-alkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkenyl, five to six membered heterocycloalkyl, halo, -COOH, -CONH₂, C₁-C₆-carboxyl, halo-C₁-C₆-alkyl, halo-C₂-C₆-alkynyl, hydroxyl, C₁-C₆-alkoxy, thio-C₁-C₆-alkoxy, C₂-C₆-alkenyloxy, halo-C₁-C₆-alkoxy, halo-C₂-C₆-alkenyloxy, nitro, amino, N-hydroxy-imidamide, nitro-C₁-C₆-alkyl, nitro-C₂-C₆-alkenyl, nitro-C₂-C₆-alkynyl, five to six ring membered nitro-heterocyclyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₂-C₆-alkenylamine, C₂-C₆-alkynylamino, C₁-C₆-acyl, C₂-C₆-alkenoyl, C₂-C₆-alkynoyl, C₁-C₆-acylamino, di-C₁-C₆-acylamino, C₁-C₆-acyloxy, C₁-C₆-alkylsulfonyloxy, five to six ring membered heterocycloxy, five to six ring membered heterocycloamino, five to six ring membered haloheterocycloalkyl, C₁-C₆-alkylsulfinyl, C₁-C₆-alkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylsulfonylamino, C₁-C₆-alkylcarbonyloxy, C₁-C₆-alkylthio, C₁-C₆-acylthio, phosphorus-containing groups such as phosphono and phosphinyl, aryl having 6 to 10 carbon atoms, five to six ring membered heteroaryl, C₁-C₄-alkylaryl having 6 or 10 carbon atoms in the aryl, five to six ring membered C₁-C₆-alkylheteroaryl, cyano, cyanate, isocyanate, -C(O)NH(C₁-C₆-alkyl), or -C(O)N(C₁-C₆-alkyl)₂ or two substituents forming an -O-C₂-C₆-alkyl-O- bridge,

Y is halo or nitro;

Z is halo or nitro;

provided that at least two of B, B¹, Y, Y¹, Z and Z¹ are not absent.

According to the present disclosure, the casein kinase 1 inhibitor is added about 3 to 4 days after the mesoderm has been established. This allows the use of small molecules which specifically address the CK1 inhibition of the Wnt pathway at this later stage.


Advantageously, small molecules of formula (I) or (II) then even show an action which is not present when they are used earlier (day 0-2). The late application window also improves the results on differentiation as shown by higher percentages of cardiomyocytes obtained. A set time frame between days 3 to 8 allows a wider range of compounds to be tested using the method of the invention without changing the concentration of the small molecules added. This is a great

advantage, which can reduce the number of experiments to one concentration and one time course in order to investigate the correlations between a compound's *in vitro* effect on target protein(s) and its cardiomyogenic activity. Moreover the effect of the compounds of formula (I) or (II) on cardiomyogenesis in the days 4 to 8 time course indicates a preferred new late stage application time slot.


According to the present disclosure, there is provided a method wherein the compound CHIR99021 is added to the embryoid bodies after the mesoderm has been established. Advantageously this results in even higher yields of cardiomyocytes of over 50 %.

According to the present disclosure, there is provided novel compounds. Such compounds include compounds of the formula (I) or (II) or a stereoisomer, tautomer, or salt thereof:

[Formula (I)]



[Formula (II)]



wherein R¹ represents fluorine substituted monovalent and divalent, single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms;

R² represents fluorine substituted aromatic hydrocarbons having 6 carbon atoms;


R³ represents saturated 5 to 6 ring membered heterocycloalkyl having 1 to 3 hetero atoms selected from N or O, or an aromatic radical having 5 to 6 ring atoms wherein 1 to 3 atoms are heteroatoms selected from O and N; and

X represents NH or O.


Advantageously these novel group of compounds and the other compounds described in the specification have been proven to be especially well suited to use in the method of the invention and to achieve the abovementioned benefits of improved differentiation.


According to the disclosure, there is provided a compound selected from the following compounds, or a stereoisomer, tautomer, or a salt thereof:

3a








3b







3d






According to another aspect, there is provided a compound selected from the following compounds, or a stereoisomer, tautomer, or a salt thereof:





According to another example, there is provided a compound selected from the following compounds, or a stereoisomer, tautomer, or a salt thereof:




According to another aspect, there is provided use of a compound of the formula (I) or (II) as defined herein, or a compound of the formula (Ia) as defined herein, or a stereoisomer, tautomer, or a salt thereof, together with excipients, in the manufacture of a kit for the

treatment of heart diseases, wherein said kit comprises said compound and a label or instructions for the use thereof.


According to another example, there is provided a kit for use in stem cell differentiation to cardiomyocytes via inhibition of casein kinase 1 comprising a compound of the formula (I) or (II) as defined herein, or a stereoisomer, tautomer, or a salt thereof, together with excipients.

According to the disclosure, there is provided a kit for use in stem cell differentiation to cardiomyocytes via inhibition of casein kinase 1 comprising a compound of the formula (I) or (II), or a stereoisomer, tautomer, or a salt thereof:

[Formula (I)]



[Formula (II)]



wherein R¹, R² and R³ independently from another represent hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl;

X represents NR⁴, O or S; and

R⁴ represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl, together with excipients.

According to another aspect, there is provided a kit for use in stem cell differentiation to cardiomyocytes *in vivo*, comprising a compound as defined herein, or a stereoisomer, tautomer, or a salt thereof, together with excipients. According to another example, there is provided a kit for use in stem cell differentiation to cardiomyocytes comprising a compound as defined herein or a stereoisomer, tautomer, or a salt thereof together with excipients. There is provided the use of any compound as defined herein for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocytes.

According to another aspect, there is provided compound as defined herein for use in inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocytes *in vivo*.

According to another example, there is provided compound as defined herein for use in inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocytes.

There is provided the use of any compound of the formula (I) or (II) as defined herein for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocytes by acting on casein kinase 1.

According to another aspect, there is provided use of a compound of the formula (I) or (II) as defined herein, or a compound of the formula (Ia) as defined herein, or a stereoisomer, tautomer, or a salt thereof, together with excipients, in the manufacture of a medicament for the treatment of heart diseases.

According to another example, there is provided compound of the formula (I) or (II) as defined herein for use in inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocytes by acting on casein kinase 1

Definitions

The following words and terms used herein shall have the meaning indicated:

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.

As used herein, the term "alkyl group" includes within its meaning monovalent ("alkyl") and divalent ("alkylene") straight chain or branched chain saturated aliphatic groups having from 1 to 10 carbon atoms, eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. For example, the term alkyl includes, but is not limited to, methyl, ethyl, 1-propyl, isopropyl, 1-butyl, 2-

butyl, isobutyl, tert-butyl, amyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, pentyl, isopentyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2-trimethylpropyl, 1,1,2-trimethylpropyl, 2-ethylpentyl, 3-ethylpentyl, heptyl, 1-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimethylpentyl, 1,2,3-trimethylbutyl, 1,1,2-trimethylbutyl, 1,1,3-trimethylbutyl, 5-methylheptyl, 1-methylheptyl, octyl, nonyl, decyl, and the like.

The term "alkenyl group" includes within its meaning monovalent ("alkenyl") and divalent ("alkenylene") straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms and having at least one double bond, of either E, Z, cis or trans stereochemistry where applicable, anywhere in the alkyl chain. Examples of alkenyl groups include but are not limited to ethenyl, vinyl, allyl, 1-methylvinyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1,3-pentadienyl, 2,4-pentadienyl, 1,4-pentadienyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 2-methylpentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 1-octenyl, 1-nonenyl, 1-decenyl, and the like.

The term "alkynyl group" as used herein includes within its meaning monovalent ("alkynyl") and divalent ("alkynylene") straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms and having at least one triple bond anywhere in the carbon chain. Examples of alkynyl groups include but are not limited to ethynyl, 1-propynyl, 1-butyne, 2-butyne, 1-methyl-2-butyne, 3-methyl-1-butyne, 1-

pentynyl, 1-hexynyl, methylpentynyl, 1-heptynyl, 2-heptynyl, 1-octynyl, 2-octynyl, 1-nonyl, 1-decynyl, and the like.

The term “cycloalkyl” as used herein refers to cyclic saturated aliphatic groups and includes within its meaning monovalent (“cycloalkyl”), and divalent (“cycloalkylene”), saturated, monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon radicals having from 3 to 10 carbon atoms, e.g., 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. Examples of cycloalkyl groups include but are not limited to cyclopropyl, 2-methylcyclopropyl, cyclobutyl, cyclopentyl, 2-methylcyclopentyl, 3-methylcyclopentyl, cyclohexyl, and the like.

“Heterocyclyl” or “heterocyclic” refer to a saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms and from 1 to 4 hetero atoms selected from the group consisting of nitrogen, sulfur or oxygen within the ring wherein, in fused ring systems, one or more the rings can be cycloalkyl, aryl or heteroaryl provided that the point of attachment is through the heterocyclic ring. Examples of heterocyclyls include, but are not limited to pyridinyl, pyrrolyl, indolyl, thienyl, furyl, benzothienyl, benzofuranyl, imidazolyl, benzoimidazolyl, pyrazolyl, thiazolyl, benzothiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, purinyl, quinolyl, isoquinolyl, dihydroquinolyl, 2,3-dihydro-1H-indolyl, quinoxalyl, benzodioxolyl, indanyl, indenyl, triazolyl, azetidyl, indolizyl, dihydroindolyl, indazolyl, quinolizyl, phthalazyl, naphthylpyridyl, quinazolyl, cinnolyl, pteridyl, carbazolyl, carbolyl, phenanthridyl, acridyl, phenanthrolyl, phenazyl, phenoxazyl, phenothiazyl, imidazolidyl, imidazolyl, piperidyl, piperazyl, indolyl, phthalimidyl, 1,2,3,4-tetrahydro-isoquinolyl, 4,5,6,7-tetrahydrobenzo[b]thiophenyl, thiazolidyl, morpholyl, thiomorpholyl (also referred to as thiamorpholyl), piperidyl, pyrrolidyl, pyrrolinyl, pyrazolidyl, pyrazolidyl and tetrahydrofuranyl.

The term “aryl” as used herein refers to monovalent (“aryl”) and divalent (“arylene”) single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms. Examples of such groups include phenyl, biphenyl, naphthyl, phenanthrenyl, and the like.

The term “heteroaromatic group” and variants such as “heteroaryl” or “heteroarylene” as used herein, includes within its meaning monovalent (“heteroaryl”) and divalent (“heteroarylene”), single, polynuclear, conjugated and fused aromatic radicals having 6 to 20 atoms wherein 1 to 6 atoms are heteroatoms selected from O, N, NH and S. Examples of such groups include pyridyl, 2,2'-bipyridyl, phenanthrolyl, quinolyl, thiophenyl, and the like.

The term “aromatic radical” may refer to aryl or heteroaryl radicals unless otherwise specified.

The term “halogen” or variants such as “halide” or “halo” as used herein refers to fluorine, chlorine, bromine and iodine.

The term “heteroatom” or variants such as “hetero-” as used herein refers to O, N, NH and S.

The term "aralkyl" as used herein, includes within its meaning ("aryl") and divalent ("arylene"), single, polynuclear, conjugated and fused aromatic hydrocarbon radicals attached to divalent, saturated, straight and branched chain C₁-C₆-alkylene radicals.

The term "heteroaralkyl" as used herein, includes within its meaning monovalent ("heteroaryl") and divalent ("heteroarylene"), single, polynuclear, conjugated and fused aromatic hydrocarbon radicals attached to divalent saturated, straight and branched chain C₁-C₆-alkylene radicals.

Preferably the aryl or arylene in the aralkyl has 6 or 10 carbon atoms. Preferably the heteroaryl or heteroarylene in the heteroaralkyl forms a five or six membered ring having 1 to 3 hetero atoms selected from N, S or O.

The term "optionally substituted" as used herein means the group to which this term refers may be unsubstituted, or may be substituted with one or more groups independently selected from C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, thio-C₁-C₆-alkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkenyl, five to six membered heterocycloalkyl, halo, -COOH, -CONH₂, C₁-C₆-carboxyl, halo-C₁-C₆-alkyl, halo-C₂-C₆-alkynyl, hydroxyl, C₁-C₆-alkoxy, thio-C₁-C₆-alkoxy, C₂-C₆-alkenyloxy, halo-C₁-C₆-alkoxy, halo-C₂-C₆-alkenyloxy, nitro, amino, nitro-C₁-C₆-alkyl, nitro-C₂-C₆-alkenyl, nitro-C₂-C₆-alkynyl, five to six ring membered nitro-heterocyclyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₂-C₆-alkenylamine, C₂-C₆-alkynylamino, C₁-C₆-acyl, C₂-C₆-alkenoyl, C₂-C₆-alkynoyl, C₁-C₆-acylamino, di-C₁-C₆-acylamino, C₁-C₆-acyloxy, C₁-C₆-alkylsulfonyloxy, five to six ring membered heterocycloxy, five to six ring membered heterocycloamino, five to six ring membered haloheterocycloalkyl, C₁-C₆-alkylsulfenyl, C₁-C₆-alkylcarbonyloxy, C₁-C₆-alkylthio, C₁-C₆-acylthio, phosphorus-containing groups such as phosphono and phosphinyl, aryl having 6 to 10 carbon atoms, five to six ring membered heteroaryl, C₁-C₄-alkylaryl having 6 or 10 carbon atoms in the aryl, five to six ring membered C₁-C₆-alkylheteroaryl, cyano, cyanate, isocyanate, -C(O)NH(C₁-C₆-alkyl), and -C(O)N(C₁-C₆-alkyl)₂. If the term "optionally substituted" is used it refers to all substituents listed after this term, e.g. "optionally substituted methyl or ethyl" means "optionally substituted methyl" or optionally substituted ethyl". The term "substituted" as used herein means the group to which this term refers may be substituted with one or more groups which are independently selected from the list of substituents mentioned.

The present invention includes within its scope all isomeric forms of the compounds disclosed herein, including all tautomers, diastereomeric isomers, racemates and enantiomers, unless the stereochemistry is fixed in the formula drawing. Thus, the formulas should be understood to include, for example, E, Z, cis, trans, (R), (S), (L), (D), (+), and/or (-) forms of the compounds, as appropriate in each case, unless the stereochemistry is fixed in the formula drawing. Tautomers can be especially mentioned.

Unless specified otherwise, the terms "comprising" and "comprise", and grammatical variants thereof, are intended to represent "open" or "inclusive" language such that they include recited elements but also permit inclusion of additional, unrecited elements.

As used herein, the term "about", in the context of concentrations of components of the formulations, typically means +/- 5% of the stated value, more typically +/- 4% of the stated value, more typically +/- 3% of the stated value, more typically, +/- 2% of the stated

value, even more typically +/- 1% of the stated value, and even more typically +/- 0.5% of the stated value.

Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.


Certain embodiments may also be described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the disclosure. This includes the generic description of the embodiments with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

Detailed Disclosure of Embodiments


Non-limiting examples of the invention and a comparative example will be further described in greater detail by reference to specific examples, which should not be construed as in any way limiting the scope of the invention.

According to a first aspect, there is provided a method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof:

[Formula (I)]



[Formula (II)]



wherein R¹, R² and R³ independently from another represent hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl;

X represents NR⁴, O or S; and

R⁴ represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl.

The casein kinase inhibitor is preferably selected from casein kinase 1 δ (delta) inhibitors or casein kinase 1ε (epsilon) inhibitors. Therefore according to the method the canonical pathway of Wnt inhibition is addressed by CK 1 δ and/or CK 1 ε inhibition.

The inhibition of the Wnt pathway has been done in a mesoderm developmental stage of the stem cells. The small molecules in according to formula (I), (Ia), (Ia)' and (II) can work

independently of those time course restrictions due to their mechanism of action on CK1. Compared to other protocols for generating cardiomyocytes, the usage of the presented small molecules is flexible.

The pluripotent stem cells in the method of the invention can be human induced pluripotent stem cells (hiPSCs) or human embryonic stem cells (hESCs). They can be harvested as embryonic bodies (EBs) according to known methods and used as such in the culture medium for differentiation according to the inventive method. The small molecules of formula (I), (Ia), (Ia)' and (II) are added according to specific time points as mentioned below. The 2,4,5-tri-substituted azoles for cardiac differentiation are robust across several embryonic-, and induced pluripotent stem cell lines.

The inventive method can be applied on different cell culture platforms. Cell culture platforms that can be especially mentioned are embryonic bodies and microcarriers. Microcarriers (MC) are tiny spheres or particles (typically 90–300 μm in diameter) used for culturing adherent cells in stirred-tank bioreactors. EBs are 3-dimensional cell aggregates that mimic some structure of the developing embryo and can differentiate into cells of all three germ layers. EBs are beneficiary in the initiation of lineage-specific differentiation towards many lineages such as cardiac.

The inventive method can be modified to have a harvesting step at the end about 10 to 12 days after the start of the differentiation.

The compounds of formula (I), (Ia), (Ia)' and (II) can be used in the typical concentration ranges of small molecules in such culture medium differentiation such as 0.5 to 20 μM , preferably 1 to 10 μM . However the compounds can also be effectively added at concentrations below 3 μM . A concentration range of 0.1 to 3 μM can be specifically mentioned. Preferred concentrations that still lead to very good differentiation results include 0.5 μM , 1 μM , 2 μM , 3 μM or 5 μM .

The cultivation temperature in the inventive methods during differentiation is usually about 37°C.

The medium for the cultivation of the stem cells can be a typical cultivation medium known in the art, such as basic serum free stem cell medium. Examples of suitable media and excipients are given in the examples. Such media include DMEM or RPMI with or without B27 supplements. The choice of the medium is however not critical.

The compound of formula (I), (Ia), (Ia)' and (II) can be used at different times during cell culturing, such as either from days 1-8, 2-6, 3-6 or from days 4-8 of the differentiation. Differentiation of cardiomyocytes via inhibition of CK1 can be used on human induced pluripotent stem cells and human embryonic stem cells after EB formation from day 2 onwards. Preferably the compound is added at day 1 to 8, 3 to 8 or 4 to 8 of the differentiation process after the mesoderm has been established.

The compound of formula (I), (Ia), (Ia)' and (II) can be used with several embryonic-, and induced pluripotent stem cell lines.

The compound of formula (I), (Ia), (Ia)' and (II) can be used on different 2D and 3D cell culture platforms such as embryoid bodies or microcarrier culture platforms known in the art.

According to a second aspect of the invention the casein kinase inhibitor is added about 3 to 4 days after the mesoderm has been established. Addition according to this embodiment is therefore during the late (post mesoderm) development of cardiomyocytes. This later addition of the inhibitor is only possible by using the inventive method which specifically addresses the CK 1 inhibition. Different differentiation results are obtained by later addition of the compound of formula (I), (Ia), (Ia)' and (II) then the usual addition on day 1-2 to 8. The reason is that in such preferred method only the CK 1 inhibition is used specifically. The method according to the invention is therefore suited to influence only the late (post mesoderm) development of cardiomyocytes (days 4 to 8 of differentiation). Such method has thus been unknown and leads to better differentiation rates.

In another embodiment of the method the casein kinase inhibitor is added from about day 3 to 8 after the mesoderm has been established. This means that the casein kinase inhibitor is present during this time after single addition or continuously added over the whole time.

From the embodiments it can be seen that the CK 1 inhibitor is present from day 3 to 8, or 4 to 8, during differentiation.

In formula (I) and (II), R^1 , R^2 , R^3 and R^4 and X have the following preferred definitions:

R^1 , R^2 , R^3 and R^4 preferably independently from another represent hydrogen, optionally substituted straight chain or branched chain saturated aliphatic groups having from 1 to 10 carbon atoms, optionally substituted straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms, optionally substituted straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms and having at least one triple bond anywhere in the carbon chain, optionally substituted, unsaturated or saturated 5 to 6 ring membered heterocycloalkyl having 1 to 3 hetero atoms selected from N, S, or O, optionally substituted heteroaromatic radicals having 5 to 6 ring atoms wherein 1 to 3 atoms are heteroatoms selected from O, N, NH and S or optionally substituted monovalent and divalent, single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms, and the optional substituents are in each case independently selected from one or more groups independently selected from C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, thio- C_1 - C_6 -alkyl, C_3 - C_8 -cycloalkyl, C_3 - C_8 -cycloalkenyl, five to six membered heterocycloalkyl, halo, -COOH, -CONH₂, C_1 - C_6 -carboxyl, halo- C_1 - C_6 -alkyl, halo- C_2 - C_6 -alkynyl, hydroxyl, C_1 - C_6 -alkoxy, C_1 - C_6 -alkoxycarbonyl, thio- C_1 - C_6 -alkoxy, C_2 - C_6 -alkenyloxy, halo- C_1 - C_6 -alkoxy, halo- C_2 - C_6 -alkenyloxy, nitro, amino, N-hydroxy-imidamide, nitro- C_1 - C_6 -alkyl, nitro- C_2 - C_6 -alkenyl, nitro- C_2 - C_6 -alkynyl, five to six ring membered nitro-heterocyclyl, C_1 - C_6 -alkylamino, di- C_1 - C_6 -alkylamino, C_2 - C_6 -alkenylamine, C_2 - C_6 -alkynylamino, C_1 - C_6 -acyl, C_2 - C_6 -alkenoyl, C_2 - C_6 -alkynoyl, C_1 - C_6 -acylamino, di- C_1 - C_6 -acylamino, C_1 - C_6 -acyloxy, C_1 - C_6 -alkylsulfonyloxy, five to six ring membered heterocycloxy, five to six ring membered heterocycloamino, five to six ring membered haloheterocycloalkyl, C_1 - C_6 -alkylsulfinyl, C_1 - C_6 -alkylsulfinyl, C_1 - C_6 -alkylsulfonylamino, C_1 - C_6 -alkylsulfonylamino, C_1 - C_6 -alkylcarbonyloxy, C_1 - C_6 -alkylthio, C_1 - C_6 -acylthio, phosphorus-containing groups such as phosphono and phosphinyl, aryl having 6 to 10 carbon atoms, five to six ring membered heteroaryl, C_1 - C_4 -alkylaryl having 6 or 10 carbon atoms in the aryl, five to six ring membered

C₁-C₆-alkylheteroaryl, cyano, cyanate, isocyanate, -C(O)NH(C₁-C₆-alkyl), or -C(O)N(C₁-C₆-alkyl)₂ or two substituents forming an -O-C₂-C₆-alkyl-O- bridge.

R¹ preferably represents hydrogen, optionally substituted straight chain or branched chain saturated aliphatic groups having from 1 to 10 carbon atoms, optionally substituted straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms, optionally substituted straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms and having at least one triple bond anywhere in the carbon chain, or optionally substituted monovalent and divalent, single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms. Optionally substituted aromatic hydrocarbons having from 6 to 10 carbon atoms can be especially mentioned.

R¹ more preferably represents halogen substituted monovalent and divalent, single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms. In this regard "halogen substituted" means that the corresponding moiety is at least substituted by one halogen, but can optionally be additionally substituted by other substituents. Fluorine is a preferred halogen. In this regard "fluorine substituted" means that the corresponding moiety is at least substituted by one fluorine, but can optionally be additionally substituted by other substituents.

R¹ most preferably represents fluorine substituted aryl having 6 to 10 carbon atoms. In this regard "fluorine substituted" means that the corresponding moiety is at least substituted by one fluorine, but can optionally be additionally substituted by other substituents. R¹ then preferably represents fluorine substituted C₆ to C₁₀ aryl which is optionally additionally substituted by one or more substituents selected from amino, -COOH, hydroxyl, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxycarbonyl, chlorine, bromine, iodine, nitro or a -O- C₁-C₄-alkyl-O- bridge. R² that represents a moiety that is only substituted by one or more fluorine atoms and no other substituents may however be specially mentioned.

R² preferably represents an optionally substituted aromatic radical having 6 atoms wherein 1 to 3 atoms are heteroatoms selected from O, N, NH and S or optionally substituted monovalent and divalent, single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms.

R² more preferably represents halogen substituted aromatic hydrocarbons having 6 carbon atoms. In this regard "halogen substituted" means that the corresponding moiety is at least substituted by one halogen, but can optionally be additionally substituted by other substituents. Fluorine is a preferred halogen. In this regard "fluorine substituted" means that the corresponding moiety is at least substituted by one fluorine, but can optionally be additionally substituted by other substituents.

R² most preferably represents fluorine substituted phenyl. In this regard "fluorine substituted" means that the corresponding moiety is at least substituted by one fluorine, but can optionally be additionally substituted by other substituents. R² then preferably represents fluorine substituted

phenyl which is optionally additionally substituted by one or more substituents selected from amino, -COOH, hydroxyl, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxycarbonyl, chlorine, bromine, iodine or nitro. R² that represents a moiety that is only substituted by one or more fluorine atoms and no other substituents may however be specially mentioned.

R³ more preferably represents optionally substituted, unsaturated or saturated 5 to 6 ring membered heterocycloalkyl having 1 to 3 hetero atoms selected from N, S, or O, optionally substituted heteroaromatic radicals having 6 atoms wherein 1 to 3 atoms are heteroatoms selected from O, N, NH and S, or optionally substituted monovalent and divalent, single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms.


R³ most preferably represents pyridinyl or pyranyl.

X preferably represents NH or O. X most preferably represents NH.

In formula (I) or (II) compounds are preferred which are covered by the proviso that none or only one of R¹, R² or R³ is hydrogen.

Among the compounds of formula (I) there are preferred the compounds for use in the method of the invention according to formula (I)' or a stereoisomer, tautomer, or a salt thereof:

[Formula (I)']



wherein R¹ represents phenyl or naphthyl which is substituted by amino, C₁-C₄-alkyl, C₁-C₄-alkoxy, halogen, nitro or a -O- C₁-C₄-alkyl-O- bridge.

Preferably the phenyl or naphthyl of R¹ is substituted by amino, methyl, ethyl, methoxy, ethoxy, fluorine, chlorine, bromine, iodine, nitro or a -O-(CH₂)-O bridge.


The following compounds are especially well suited to be used in the inventive method. Some of them are novel compounds which are also provided according to the invention, such as:

Compounds of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof, wherein R¹ represents fluorine substituted monovalent and divalent, single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms; R² represents fluorine substituted aromatic hydrocarbons having 6 carbon atoms; R³ represents saturated 5 to 6 ring membered heterocycloalkyl having 1 to 3 hetero atoms selected from N or O, or an aromatic radical having 5 to 6 ring atoms wherein 1 to 3 atoms are heteroatoms selected from O and N; and X represents NH.


Among the compounds, compounds wherein R^1 represents fluorine substituted C_6 to C_{10} aryl, R^2 represents fluorine substituted phenyl, R^3 represents pyridinyl or pyranyl; and X represents NH are preferred.

More preferred are the compounds and their tautomers listed in the following:


[Formula IIIa]




[Formula IIIb]




[Formula IIIc]



[Formula IIIId]




[Formula IIIc]



All of these compounds are novel except for 4-[4(5)-(4-fluorophenyl)-2-phenyl-1*H*-imidazol-5(4)-yl]pyridine (known from US 5,777,097), 4-[2-(2-methoxyphenyl)-4(5)-(4-fluorophenyl)-1*H*-imidazol-5(4)-yl]pyridine, 4-[2-(2-chlorophenyl)-4(5)-(4-fluorophenyl)-1*H*-imidazol-5(4)-yl]pyridine, 4-[4(5)-(4-fluorophenyl)-2-(2-nitrophenyl)-1*H*-imidazol-5(4)-yl]pyridine (known from WO 2004/005264) and 4-[2-(2-bromophenyl)-4(5)-(4-fluorophenyl)-1*H*-imidazol-5(4)-yl]pyridine (known from WO 2003/024447).


The compound 1a (4-(2-(2,6-difluorophenyl)-4(5)-(4-fluorophenyl)-1*H*-imidazol-5(4)-yl)pyridine; IM-31, TA-01) or its tautomer can be mentioned as especially preferred and has the following formula (1a):

[Formula 1a]



The compound 4-[2-(2-chloro-6-fluorophenyl)-5(4)-(4-fluorophenyl)-3*H*-imidazol-4(5)-yl]pyridine (ZQX-19) 1a or its tautomer can also be mentioned as especially preferred and has the following formula :

[Formula 1b]



According to the invention it has been found that these compounds have an ability to work as a cardiomyocyte inducer as well as cardiac inhibitor, when applied at high concentration pre mesoderm. This indicated another usage of these compounds beyond cardiac differentiation.

According to the invention the compounds of formula (I), (Ia), (Ia)' and (II) can also be used as cardiac inhibitor at higher concentrations or pre-mesoderm.


Furthermore IM-31 can be used at a 5 times lower concentration than comparable 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors to generate 10-20% cardiomyocytes. The compound is an outstanding compound of high technological significance not just for cardiomyocyte differentiation according to the method of the invention, but also in its ability to inhibit comparable kinase targets of SB203580 more efficiently. Using this compound, also as an example for other compounds according to the invention, a more efficient cardiomyocyte

differentiation when compared to IWP-2 (see below) with a simple medium formulation has been achieved.

The compounds 4-(2-(2-fluorophenyl)-4(5)-(4-fluorophenyl)-1*H*-imidazol-5(4)-yl)pyridine IM-30 (TA-02), 4-[2-(2-chloro-6-fluorophenyl)-4(5)-(4-fluorophenyl)-1*H*-imidazol-5(4)-yl]pyridine (ZQX-19) and 4-[2-(2-fluoro-6-methoxyphenyl)-4(5)-(4-fluorophenyl)-1*H*-imidazol-5(4)-yl]pyridine (ZQX-20) are also stronger CK 1 inhibitors than SB203580 and show higher cardiomyocyte differentiation outputs at specific time course. These compounds are also specifically mentioned. It is of technological significance as higher cardiomyocyte yields can be achieved with small molecules such as IM-31 (TA-01), IM-30 (TA-02), ZQX-19 and ZQX-20. Especially with the presented embryoid body based protocol in suspension culture it is possible to scale up the production of cardiomyocytes to a magnitude of therapeutic significance. IM-31 (TA-01) and alternatively TA-01, ZQX-19 and ZQX-20 are able to induce higher cardio differentiation when applied at the specific time course described herein.

Further compounds that can be mentioned for use in the invention are: Compounds of formula (Ia), or a stereoisomer, tautomer, or a salt thereof:


[Formula (Ia)]



wherein B, B¹, Y, Y¹, Z and Z¹ are absent or each independently selected from C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, thio-C₁-C₆-alkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkenyl, five to six membered heterocycloalkyl, halo, -COOH, -CONH₂, C₁-C₆-carboxyl, halo-C₁-C₆-alkyl, halo-C₂-C₆-alkynyl, hydroxyl, C₁-C₆-alkoxy, thio-C₁-C₆-alkoxy, C₂-C₆-alkenyloxy, halo-C₁-C₆-alkoxy, halo-C₂-C₆-alkenyloxy, nitro, amino, N-hydroxy-imidamide, nitro-C₁-C₆-alkyl, nitro-C₂-C₆-alkenyl, nitro-C₂-C₆-alkynyl, five to six ring membered nitro-heterocyclyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₂-C₆-alkenylamine, C₂-C₆-alkynylamino, C₁-C₆-acyl, C₂-C₆-alkenoyl, C₂-C₆-alkynoyl, C₁-C₆-acylamino, di-C₁-C₆-acylamino, C₁-C₆-acyloxy, C₁-C₆-alkylsulfonyloxy, five to six ring membered heterocycloxy, five to six ring membered heterocycloamino, five to six ring membered haloheterocycloalkyl, C₁-C₆-alkylsulfenyl, C₁-C₆-alkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylsulfinylamino, C₁-C₆-alkylsulfonylamino, C₁-C₆-alkylcarbonyloxy, C₁-C₆-alkylthio, C₁-C₆-acylthio, phosphorus-containing groups such as phosphono and phosphinyl, aryl having 6 to 10 carbon atoms, five to six ring membered heteroaryl, C₁-C₄-alkylaryl having 6 or 10 carbon atoms in the aryl, five to six ring membered C₁-C₆-alkylheteroaryl, cyano, cyanate, isocyanate, -C(O)NH(C₁-C₆-alkyl), or -C(O)N(C₁-C₆-alkyl)₂ or two substituents forming an -O-C₂-C₆-alkyl-O- bridge; provided that at least two of B, B¹, Y, Y¹, Z and Z¹ are not absent.

The compounds of formula (Ia)' can also be used in the inventive method.

[Formula (Ia)']



wherein B, B¹, Y, Y¹, Z and Z¹ are absent or each independently selected from C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, thio-C₁-C₆-alkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkenyl, five to six membered heterocycloalkyl, halo, -COOH, -CONH₂, C₁-C₆-carboxyl, halo-C₁-C₆-alkyl, halo-C₂-C₆-alkynyl, hydroxyl, C₁-C₆-alkoxy, thio-C₁-C₆-alkoxy, C₂-C₆-alkenyloxy, halo-C₁-C₆-alkoxy, halo-C₂-C₆-alkenyloxy, nitro, amino, N-hydroxy-imidamide, nitro-C₁-C₆-alkyl, nitro-C₂-C₆-alkenyl, nitro-C₂-C₆-alkynyl, five to six ring membered nitro-heterocyclyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₂-C₆-alkenylamine, C₂-C₆-alkynylamino, C₁-C₆-acyl, C₂-C₆-alkenoyl, C₂-C₆-alkynoyl, C₁-C₆-acylamino, di-C₁-C₆-acylamino, C₁-C₆-acyloxy, C₁-C₆-alkylsulfonyloxy, five to six ring membered heterocycloxy, five to six ring membered heterocycloamino, five to six ring membered haloheterocycloalkyl, C₁-C₆-alkylsulfenyl, C₁-C₆-alkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylsulfinylamino, C₁-C₆-alkylsulfonylamino, C₁-C₆-alkylcarbonyloxy, C₁-C₆-alkylthio, C₁-C₆-acylthio, phosphorus-containing groups such as phosphono and phosphinyl, aryl having 6 to 10 carbon atoms, five to six ring membered heteroaryl, C₁-C₄-alkylaryl having 6 or 10 carbon atoms in the aryl, five to six ring membered C₁-C₆-alkylheteroaryl, cyano, cyanate, isocyanate, -C(O)NH(C₁-C₆-alkyl), or -C(O)N(C₁-C₆-alkyl)₂ or two substituents forming an -O-C₂-C₆-alkyl-O- bridge;

- - - represents a single bond or double bond;

X represents NR⁴, O or S;

R⁴ is absent or represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl;

R⁵ is absent or represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl;

provided that one of R⁴ or R⁵ is absent and that at least two of B, B¹, Y, Y¹, Z and Z¹ are not absent.

Compounds of formula (Ia) or (Ia)' wherein at least three of B, B¹, Y, Y¹, Z and Z¹ are not absent can be specifically mentioned as preferred.


The compounds of formula (I), (Ia), (Ia)' and (II) can be prepared as described in the detailed examples or by analogous methods known by the persons skilled in the art.

All these compounds can accordingly be used for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocytes.

According to a third aspect of the invention there is provided an additional embodiment of the method wherein the compound CHIR99021 is added to the embryoid bodies before the mesoderm has been established.

CHIR99021 is an aminopyrimidine derivative of the formula (IV) that is an extremely potent inhibitor of GSK3, inhibiting GSK3 β (IC_{50} = 6.7 nM) and GSK3 α (IC_{50} = 10 nM) and functions as a Wnt activator.

[Formula (IV)]



According to a preferred embodiment CHIR99021 is added to the stem cell culture before the compounds of the CK 1 inhibitor (preferably on day 0-1 or earlier). Concentrations of CHIR99021 that can be used are in the range of about 0.1 to 20 μ M or also 2 to 20 μ M, preferably about 0.5 to 5 μ M, most preferably about 3 to 7 μ M. Such early exposure in the culture medium to CHIR99021 preferably last about 1 to 36 h, more preferably about 10 to 30 h and most preferably about 20 to 28 hours. The pretreatment with CHIR99021 at a high concentration of 3 to 7 μ M for about 20 to 28 hours can be followed by a treatment at lower concentration of 0.5 to 2 μ M is another embodiment. The CK 1 inhibitor can then be added thereafter (day 1 to 8 or, preferably, on day 3 to 8 or 4 to 8 of differentiation). The late addition on days 3 to 8 or 4 to 8 provides the best results with regard to differentiation obtainable according to this embodiment. The culture medium for the activation step with CHIR99021 can be one ordinarily known in the art, such as those disclosed in the examples.

The pre-treatment with a pre-mesoderm active small molecule, such as CHIR99021, as another step in the method according to the invention is therefore a preferred embodiment of the invention which leads to better yields and differentiation success. The CK 1 inhibitor of the formula (I), (Ia), (Ia)' or (II) is preferably applied at a concentration of 0.5 to 20 μ M or 0.5 to 5 μ M, preferably 1 to 3 μ M, in this two-step protocol of the embodiment.

According to a fifth aspect of the invention there is provided a kit for use in stem cell differentiation to cardiomyocytes via casein kinase inhibition comprising a compound of the formula (I), (Ia), (Ia)' or (II), or a stereoisomer, tautomer, or a salt thereof, wherein R^1 , R^2 and R^3 independently from another represent hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl; X represents NR^4 , O or S; and R^4 represents hydrogen, optionally substituted alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl or aryl together with excipients. The compounds of formula (I), (Ia), (Ia)' and (II) can be formulated in compositions comprising as excipients diluents, solvents, which can be buffer solutions, or other aqueous and nonaqueous carriers.

One embodiment of the invention, provides a kit for use in stem cell differentiation to cardiomyocytes comprising a compound of formula (I) or (II), wherein R^1 represents halogen substituted monovalent and divalent, single, polynuclear, conjugated and fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms; R^2 represents halogen substituted

aromatic hydrocarbons having 6 carbon atoms; R^3 represents saturated 5 to 6 ring membered heterocycloalkyl having 1 to 3 hetero atoms selected from N or O, or an aromatic radical having 5 to 6 ring atoms wherein 1 to 3 atoms are heteroatoms selected from O and N; and X represents NH, or a stereoisomer, tautomer, or a salt thereof together with excipients. Fluorine is preferred as halogen.

Another embodiment of the invention provides a kit for use in stem cell differentiation to cardiomyocytes comprising one of the above described individual compounds according to Formula's IIIa to IIIe, or a stereoisomer, tautomer, or a salt thereof together with excipients.

Additional excipients in the compositions may be adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of micro-organisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged usage ability of the composition may be brought about by the inclusion of agents that delay absorption such as aluminium monostearate and gelatin.

In such embodiment there is provided a kit comprising a container with a composition of the compound of the formula (I), (Ia), (Ia)' or (II), or a stereoisomer, tautomer, or a salt thereof, together with excipients. In such a kit or pack, a container having a unit dosage of the agent(s) may be found. The kits may include a composition comprising an effective agent either as concentrates, which may be diluted further prior to use or they can be provided at the concentration of use, where the vials may include one or more dosages. Conveniently, in the kits, single dosages can be provided in sterile vials and suitable sizes so that the scientist can employ the vials directly, where the vials will have the desired amount and concentration of agent(s). Vials with media, such as DMEM or RPMI with or without B27 supplements, can be part of the kit. Associated with such container(s) may be various written materials such as instructions for use. Such instructions for use can describe the use of the CK 1 inhibitors according to any of the inventive methods describes above. They can especially refer to an application of the CK1 inhibitor during 3 to 8 (or 4 to 8) of the differentiation or the the late (post mesoderm) development of cardiomyocytes.

Most preferred is a kit which additionally comprises the compound CHIR99201. This kit can be used in the preferred embodiment of the inventive method mentioned above. Preferably CHIR99201 is added in a separate container in the kit, e.g. together with instructions when to apply it in relation to the CK 1 inhibitor. Preferably it describes a two step protocol of first applying the compound CHIR99201 and then applying the casein inhibitor of formula (I) or (II) during the late (post mesoderm) development of cardiomyocytes.

Examples

Example 1: Materials and Methods

In the examples described below, unless otherwise indicated, all temperatures in the following description are in degrees Celsius and all parts and percentages are by weight, unless indicated otherwise. Reagents useful for synthesizing compounds may be purchased from commercial suppliers, such as Sigma-Aldrich Pte Ltd, Life Technologies or others and used without further purification, unless otherwise indicated, or obtained or prepared according to techniques known in the art.

The identity of all compounds was assessed after purification by HRMS-ESI analyses on an Agilent 6200 series accurate-mass time-of-flight (TOF) LC/MS in electrospray ionization (ESI) positive mode.

All the 1D and 2D NMR experiments for ^1H (400.13 MHz), nuclei were performed on a Bruker AVANCE-400 digital NMR spectrometer. NMR spectra are reported in ppm with reference to an internal tetramethylsilane standard (0.00 ppm for ^1H) or solvent peak(s) of CDCl_3 (7.26 and 77.1 ppm) or CD_3OD (3.31 and 49.0 ppm), or $\text{DMSO}-d_6$ (2.50 and 39.5 ppm). Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplets, bs = broadened singlet. Coupling constants, when given, are reported in hertz.

List of abbreviations used

Names/terms	Abbreviations	Names/terms	Abbreviations
Acetate	OAc	Phenyl	Ph
Dimethyl sulfoxide	DMSO	Acetic acid	AcOH
Phosphate buffered saline	PBS	Nuclear Magnetic Resonance	NMR
Bovine serum albumine	BSA	Ethyl	Et
equivalent	equiv	Tetrahydrofuran	THF
High-performance liquid chromatography or high-pressure liquid chromatography	HPLC	Dichlormethane	DCM
high-resolution mass spectrometry	HRMS	Room temperature	rt
n-Butyllithium	ⁿ BuLi	Lithium bis(trimethylsilyl)amide	LiHMDS
1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone	DMPU	N-Bromosuccinimide	NBS
Dicyclohexyl(2',6'-diisopropoxy-2-biphenyl)phosphine	RuPhos	Pivalic acid	PivOH

Culture of HESCs

hESC3 Nkx2.5^{eGFP/w} (reporter cell line for cardiac differentiation kindly provided from David Elliot Lab. Melbourne Australia, see Nat Methods. 2011 Oct 23;8(12):1037-40. doi: 10.1038/nmeth.1740, NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes, Elliott DA1, Braam SR, Koutsis K, Ng ES, Jenny R, Lagerqvist EL, Biben C, Hatzistavrou T, Hirst CE, Yu QC, Skelton RJ, Ward-van Oostwaard D, Lim SM, Khammy O, Li X, Hawes SM, Davis RP, Goulburn AL, Passier R, Prall OW, Haynes JM, Pouton CW, Kaye DM, Mummery CL, Elefanty AG, Stanley EG) was cultured on irradiated mouse embryonic fibroblasts derived from the progeny of 129X1/SvJ mice, in DMEM/F12 medium supplemented with 20% Knockout serum replacement (KSR), 1% nonessential amino acid solution, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM L-glutamine, 0.1 mmol/L β-mercaptoethanol, and 10 ng/ml basic fibroblast growth factor, all procured from Life Technologies.

hESC7 (H7, see Science 6 November 1998: Vol. 282 no. 5391 pp. 1145-1147; DOI: 10.1126/science.282.5391.1145; Report Embryonic Stem Cell Lines Derived from Human Blastocysts; James A. Thomson, Joseph Itskovitz-Eldor, Sander S. Shapiro, Michelle A. Waknitz, Jennifer J. Swiergiel, Vivienne S. Marshall, Jeffrey M. Jones) and hiPSC 00208 (derived in University of Tampere, kindly provided by Dr. Katriina Aalto-Setälä) were cultured on irradiated mouse embryonic fibroblasts derived from the progeny of 129X1/SvJ mice, in Knockout DMEM supplemented with 20% Knockout serum replacement (KSR), 1% nonessential amino acid solution, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM L-glutamine, 0.1 mmol/L β-mercaptoethanol, and 100 ng/ml basic fibroblast growth factor, all procured from Life Technologies.

All media was refreshed daily and cultures were passaged every 4-5 days. Cultures were incubated at 37 °C in a humidified atmosphere with 5% CO₂.

Cardiomyocyte differentiation and analyses

hESC and hiPSC were harvested in 100µm clumps and seeded at 2.2×10^6 cells/well as EBs in ultra-low attachment 12-well plates (Nunc) in basic serum free stem cell (bSFS) medium: DMEM (Life Technologies) supplemented with 2 mM L-glutamine (Life Technologies), 0.182 mM sodium pyruvate (Life Technologies), 1% non-essential amino acids (Life Technologies), 0.1 mM β-mercaptoethanol, 5.6 mg/L transferrin (Life Technologies), 20 µg/L sodium selenite (Sigma), 0.5% (w/vol) Bovine Serum Albumin (Life Technologies) and 0.25% (w/vol) Hysoy (Sheffield Bioscience). Cells were incubated for 24h at 37 °C and 5% CO₂ to allow EB formation. The medium was refreshed thereafter and then every 2-3 days, cells were stimulated with the respective compounds (Table 1 and 2) in equal amounts of DMSO (1 µl DMSO/ml of media) (Sigma-Aldrich) at a specific time course.

EBs were harvested 11 days after differentiation induction and dissociated in a single suspension by incubation for 8-12 min in TrypLE (Invitrogen). Cell number and viability was evaluated with Nucleocount according to the manufacturer's protocol. The harvested single suspension cells were fixed and permeabilized (FIX&PERM, BD).

Cells were incubated with cardiac troponin T (dilution at 1:400, Pierce) and cardiac atrium antibody MLC2a (dilution 1:800, SYSY Synaptic Systems) antibodies for 30min, and detected with an appropriate secondary antibody Alexa Fluor 647 (1:500, Life Technology) on flow cytometer Guava (Millipore) using Flowjo software.

Cyto-immunofluorescence was performed on 16 days old embryoid bodies (EBs). EBs were transferred on day 6 onto attachment plates to allow cells to grow out onto objective material. EBs and cells were fixed with 4% paraformaldehyde for 30 minutes at room temperature. Cells were incubated with cardiac troponin T (dilution at 1:200, Pierce), sarcomeric actinin (dilution at 1:200, Sigma-Aldrich), cardiac atrium antibody MLC2a (dilution 1:400, SYSY Synaptic Systems), and muscle mesoderm marker MEF2C (dilution 1:200, Cell Signaling) antibodies in 3% BSA-PBS with 0.2% Triton-X overnight. Appropriate secondary antibody Alexa Fluor 488 and

594 (1:500; Life Technologies) were used to detect the signal with an Olympus fluorescence microscope. Nuclear stains for cell detection were DAPI (R&D) and DracQ (Cell Signaling). Multilayer fluorescence images were combined with Image J.

Detailed cardiomyocyte differentiation protocol and flow cytometer analyses

Preparations: Stem cells were expanded on 10 centimeter culture dishes for 5-6 days to 80-90% confluence prior experiment. One standard culture dish provides enough material (approx. 28×10^6 cells) for one 12-well plate experiment.

1. Wash stem cells with PBS $\times$ 1 (without Mg and Ca)
2. Submerge with PBS $\times$ 1 (without Mg and Ca)
3. Remove feeder and non-colony like (differentiated) stem cells by aspirating with a sharp tip (20 μ m tip)
4. Submerge in basic serum free stem cell differentiation media (bSFS) (6-8 ml)
5. Use a passaging tool (EZ passaging tool, Life Technology) for stem cells to cut in vertical and horizontal directions to obtain cell cluster squares of similar dimensions of about 50-100 μ m
6. Separate floating clusters meshes very carefully to minimize cell death by pipetting up and down with a serological pipette.
7. Leave stem cells clusters to sediment in petri dish for 5-10min
8. Aspirate at least 2/3 of the volume to remove floating feeder cells and single stem cells, but not the stem cell clusters
9. Add 20 ml bSFS medium
10. Estimate viability and cell number
11. Seed between $2.2-2.5 \times 10^6$ cells/well (total cell count with minimum viability 75%) in ultralow attachment 12-well plates.
12. Adjust total volume per well to 2 ml. (Minimum media per well is 1.5 ml maximal 3 ml.)
13. Optional for high efficiency differentiation: Add CHIR99021 diluted in DMSO per well at 3 μ M for hESC3, 4 μ M for hESC7 and 2-3 μ M for hiPSC for 24h.
14. Disperse stem cell clumps evenly over the surface (don't let them cluster in the middle)
15. Place cell culture for overnight or 24h under culture condition
16. Change bSFS medium (2-3 ml) and remove all small cluster below 150 micron as much as possible
17. Optional differentiation protocol for days 1-8 or 1-3: Add compounds dissolved in DMSO at 1 μ l/ml at desired μ M concentration (Table 1 and 2) to the cultures and mix well.
18. Disperse embryoid bodies evenly over the surface and leave cell culture for further 3 days under culture condition
19. Change bSFS medium (2-3 ml) and add compounds dissolved in DMSO at 1 μ l/ml at desired μ M concentration (Table 1 and 2) to the cultures
20. Refresh bSFS media with compounds every 2 days for the next 4 days
21. Refresh only bSFS media (3 ml) and culture for 3 more days

22. Analyze embryoid bodies (beat count, beat frequency, flow cytometry, cyto-immunofluorescence and cell count)

Evaluation of cardiomyocyte differentiation with flow cytometer

1. Transfer all embryoid bodies (EBs) from 12 well plates to a 1.5 ml Eppendorf tube on day 11/12 of experiment.
2. Spin cells down at 13000 rpm for 30sec and aspirate supernatant
3. Wash cells once with PBS-/- (without calcium and magnesium)
4. Spin cells down at 13000 rpm for 30sec and aspirate supernatant
5. Digest cells with 500 μ L TrypLE (Life Technology)
6. Incubate at 37 °C water bath with shaking (tapping the eppendorf tube from time to time) for 8min (max 15min).
7. Add 500 μ L culture medium to stop the digestion and pipette up and down to break down cell clusters to an homogeneous suspension
 - a. Optional: Cell count
 - b. Aliquot 95 μ L to a new eppendorf tube
 - c. Add 5 μ L of solution 13 (Nucleocount) and mix well
 - d. Load 10 μ L of the solution into the glass probe
 - e. Perform the read out (assay: single cell and viability) with Nucleocounter
8. Repeat washing step 2-4
9. Strain cells through a 20-40 μ m nylon mesh or mesh plate to remove cell clumps
 - a. Optional: Fixation and cyto-immunofluorescence (cTnT and MLC2a)
 - b. Fix cells with 100 μ L BD cytofix/cytoperm (BD kit) for 20min on ice
 - c. Wash cell twice with 1 $\times$ Perm/Wash buffer (BD kit)
 - d. Resuspend cells in flow buffer (PBS 1% bovine serum albumin) with cTnT antibody 1:400 or MLC2a 1:800
 - e. Incubate on ice in dark for 30min
 - f. Add 100 μ L flow buffer and spin down at 13000 rpm for 30sec
 - g. Wash cells once again with flow buffer
 - h. Resuspend cells with flow buffer with second antibody (Alexa Fluor-647 goat anti-mouse IgG1, 1:500)
 - i. Incubate on ice in dark for 20min
 - j. Add 100 μ L flow buffer and spin down at 13000 rpm for 30sec
 - k. Wash cells once again with flow buffer
10. Resuspend not more than 200,000 cells/ml in flow buffer (PBS 1% bovine serum albumin)
11. Transfer 250 μ L in 96-well U-bottom plates (Greiner)
12. Perform read out fluorescence with the flow cytometer (Guava, Millipore)

Functional assay of developed cardiomyocytes

Microscopic videos from the culture wells were captured via a camera mounted on a Nikon Eclipse Ti microscope platform and later analyzed to objectively identify and quantify beating aggregates in terms of frequency, amplitude, size, etc. In order to maintain cultures for long term, cultures on the platform were kept at 37 °C with 5% CO₂ via an on-stage incubator.

Alternative high efficiency cardiomyocyte differentiation methods (Figures 9 to 11)

Culture of HESCs for the alternative cardiomyocyte differentiation methods

Human embryonic stem cell (hESC) lines HES-3 (NKS2.5^{eGFP/w} reporter cell line for cardiac differentiation kindly provided from David Elliot Lab. Melbourne Australia) and H7, as well as human induced pluripotent stem cell (IPS) lines IMR-90, Donor 11 (in-house IPS cell line) and IPS00208 (derived in University of Tampere, kindly provided by Dr. Katriina Aalto-Setälä) were cultured on Geltrex® coated (Gletrex, Life Technologies) in E8 medium (Life technologies). All media was refreshed daily and cultures were passaged every 4-5 days. Cultures were incubated at 37°C in a humidified atmosphere with 5%CO₂. Plates with a 50-70% confluence were used for experiments.

Differentiation in 96-U bottom ultra-low attachment well plates (Figure 9)

Human embryonic stem cell (hESC) lines HES-3 (NKS2.5^{eGFP/w} reporter cell line for cardiac differentiation kindly provided from David Elliot Lab. Melbourne Australia) were dissociated with TrypLE (Invitrogen) and seeded at 1.5×10^4 cells/well in ultra-low attachment 12-well plates (Nunc) in bSFS medium: DMEM or RPMI (Life Technologies) supplemented with 2mM L-glutamine (Life Technologies), 0.182mM sodium pyruvate (Life Technologies), 1% non-essential amino acids (Life Technologies), 0.1mM β -mercaptoethanol, 5.6mg/L transferrin (Life Technologies), 20 μ g/L sodium selenite (Sigma), 0.5% (w/vol) Bovine Serum Albumin (Life Technologies) and 0.25% (w/vol) Hysoy (Sheffield Bioscience). Cells were spun down at 400rpm to form an EB and incubated for 24h with 6 μ M CHIR99021 (Selleck, US), 7.5 μ M Y27632 (Selleck, US) and 50 μ g/ml Matrigel® (BD, UK) at 37 °C and 5%CO₂ to allow EB formation. The medium was refreshed thereafter and the CHIR99021 concentration was lowered to 1.5 μ M. 24h later the cells were supplied with fresh bSFS medium. On day 2 or 3 EBs were stimulated with the respective inhibitor compounds (Table 1) in equal amounts of DMSO (1 μ l DMSO/ml of media) (Sigma-Aldrich) for 5 days.

On day 14 Microscopic images of each EB were captured via a camera mounted on a Nikon Eclipse Ti microscope platform in phase contrast mode and with fluorescence imaging. Images were analyzed to objectively identify and quantify green fluorescence areas, and embryoid body size with Image J®. The cultures on the platform were kept at 37°C with 5% CO₂ via an on-stage incubator.

Differentiation in 12-Well ultra-low attachment plates (Figure 10)

hESC (H7) and IPS (Donor 11, IMR-90) were harvested in 100 μ m clumps and seeded at 2.2×10^6 cells/well as EBs in ultra-low attachment 12-well plates (Nunc) in bSFS medium: DMEM (Life Technologies) supplemented with 2mM L-glutamine (Life Technologies), 0.182mM sodium pyruvate (Life Technologies), 1% non-essential amino acids (Life Technologies), 0.1mM β -mercaptoethanol, 5.6mg/L transferrin (Life Technologies), 20 μ g/L sodium selenite (Sigma), 0.5% (w/vol) Bovine Serum Albumin (Life Technologies) and 0.25% (w/vol) Hysoy (Sheffield Bioscience). Cells were incubated for 24h with 6 μ M CHIR99021 (Selleck, US) at 37 °C and 5%CO₂ to allow EB formation. The medium was refreshed

thereafter and the CHIR99021 concentration was lower to 1.5 μ M. 24h later we supplied the cells with fresh bSFS medium, cells were stimulated with the respective TA compounds in equal amounts of DMSO (1 μ l DMSO/ml of media) (Sigma-Aldrich) for 6 days.

EBs were harvested 14 days after differentiation induction and dissociated in a single suspension by incubation for 8-12 min in TrypLE (Invitrogen). Cell number and viability was evaluated with Nucleocount according to the manufacturer's protocol. The harvested single suspension cells were fixed and permeabilized (FIX&PERM, BD).

Cells were incubated with cardiac Troponin T (dilution at 1:400, Pierce) and cardiac atrium antibody MLC2a (dilution 1:800, SYSY Synaptic Systems) antibodies for 30min, and detected with an appropriate secondary antibody Alexa fluor 647 (1:500, Life Technology) on flow cytometer Guava (Millipore) using Flowjo software.

Differentiation on microcarriers (Figure 11)

HES-3 were seeded at 2×10^5 cells/ml in the 50 ml spinner flask that contained 25 ml hESC medium and 200 mg PLL + LN-coated MC (poly-L-lysine and laminin coated microcarrier). The sample was incubated at 37°C/5% carbon dioxide for 24 hours in static conditions, after which another 25 ml hESC medium were added and the culture was then agitated at 30 rpm for 6 days. Eighty per cent of the spent medium was replaced daily with fresh hESC medium. The cell concentration and cell viability were determined daily using a Nucleocounter NC-3000 (Chemometec, Davis, CA, USA). Pluripotent markers were measured by flow cytometry on day 7. The size of the hESC/MC aggregates was measured from images taken using an Olympus IX70 microscope (Olympus, Shinjuku-ku, Tokyo, Japan), with average dimensions determined using NIH image J software.

About 50 hESC/MC aggregates from spinner cultures were incubated in a 12-well ultra-low attachment plate (Nunc, Rochester, NY, USA) and directly subjected to cardiac differentiation simply by changing the hESC medium into 15 μ M CHIR99021 containing DMEM or RPMI with B27 supplements based differentiation medium. After 24 hours the differentiation medium was replenished, and 5 μ M IWP-2 or TA-01 was added at day 3. This IWP-2 and TA-01 was removed during the medium exchange on day 5. Cells were then maintained in differentiation medium with insulin from day 11 until day 20 followed by IWP-2, TA-01 treatment. On day 20 of the differentiation protocol, cells from all cultures were harvested and analyzed by fluorescence-activated cell sorting (FACS) for cardiac markers MLC2a and Troponin T (cTnt) and MF20.

Example 2: Synthesis of compounds

The target compounds were synthesized using routes outlined in Figures 1 to 5. All of the synthesized imidazoles with unsubstituted N1 nitrogen were obtained as a mixture of annular tautomers which rapidly interconvert in solution. For compounds containing a chiral centre, they were synthesized as a racemic mixture of stereoisomers and applied in the biological studies as a racemic mixture. Details of the synthesis of the compounds are as follows:

All of the synthesized compounds (except IM-44) possess the 2,4,5-tri-substitution pattern on the azole core structure and can be classified according to the general structures shown in Figure 1.

Compounds **1a** – **1c** and other compounds containing the vicinal pyridin-4-yl/4-fluorophenyl moiety similar to SB203580 were synthesized according to Figure 2. Sonogashira coupling between 4-fluorophenylacetylene **6** and 4-bromopyridine **7** gave 1,2-disubstituted alkyne **8** which was oxidized to 1,2-diketone **9** using potassium permanganate under slightly basic conditions. Diketone **9** was then condensed with the appropriate aldehydes and ammonium acetate under acidic conditions to give imidazoles **1a** – **1c**. Diketone **9** was also condensed with the appropriate aldehydes and ammonium acetate under acidic conditions to give imidazoles ZQX-14-23 and ZQX-25-32.

The synthesis of compounds **2a** – **2e** containing the vicinal pyridin-4-yl/3-tolyl moiety had been reported in Low, J. L. et al. *Bioorg Med Chem Lett* **2013**, 23, 3300. Other compounds containing the vicinal pyridin-4-yl/3-tolyl moiety (**2f** – **2t**) were synthesized as shown in Figure 3. Imidazoles **2f** – **2h** and **2t** were obtained through the condensation reaction of 1,2-diketone **10a** and **10b** respectively with the various aldehydes and ammonium acetate in acetic acid. Condensation of 1,2-diketone **10a** with 4-formylbenzonitrile gave **2i** following which reaction with hydroxylamine in refluxing ethanol gave **2j**. Compound **2k** was obtained through condensation of 1,2-diketone **10a** with 4-formylbenzoic acid. Reaction of **2k** with thionyl chloride generates the acid chloride which was then reacted with aqueous ammonia and methanol to give amide **2l** and ester **2m** respectively. Imidazole **2o** was obtained through the condensation of 4-nitrobenzaldehyde with 1,2-diketone **10a** to give **2n**, followed by reduction using palladium on carbon.

For imidazoles containing non-aromatic substituents at the C-2 position 1,2-diketone **10a** was first reacted with formaldehyde and ammonium acetate in acetic acid under microwave conditions to give 4,5-disubstituted imidazole **2p**. Heating **2p** with formaldehyde and dimethyl amine in ethanol resulted in **2q**. Iodination of **2p** at the imidazole C-2 position with N-iodosuccinimide gave compound **11** following which Sonogashira coupling with 3-butyne-1-ol gave **2r**. Compound **2s** was synthesized by first protecting the imidazole N-1 nitrogen of **2p** with trityl chloride to give compound **12** followed by nucleophilic addition to 1-cyclohexene-1-carbaldehyde to give compound **13**. Subsequent trityl deprotection of compound **13** gave compound **2s**.

With regards to the compounds containing a pyran-4-yl substituent at the imidazole C-5 position, they were synthesized according to Figure 4. The preparation of imidazoles **3a** and **4a** had been reported in Low, J. L. et al. *Bioorg Med Chem Lett* **2013**, 23, 3300, and they were not included in the scheme. Compounds **3b** – **3e** and **3f** were synthesized via condensation of 1,2-diketone **14a** and **14b** respectively with the appropriate aldehydes and ammonium acetate in acetic acid. Similarly compounds **4b** – **4k** were obtained by reacting 1,2-diketone **15** with the respective aldehydes and ammonium acetate in acetic acid.

Oxazoles OZ-06 and OZ-12 were synthesized via the sequence shown in Figure 5. The first step involved a regioselective C4 bromination of 5-substituted oxazoles **16a** and **16b** to give 4,5-disubstituted oxazoles **17a** and **17b**. A Suzuki cross-coupling reaction then installs the desired aryl group at the C4 position of oxazoles **17a** and **17b** to give 4,5-diaryl oxazoles **18a** and **18b** which then underwent direct arylation at the oxazole C2 position to give 2,4,5-triaryl oxazoles

19a and **19b**. The thiomethyl group of oxazole **19a** and **19b** was then oxidized to the methyl sulfoxide group in oxazoles OZ-06 (**5a**) and OZ-12 (**5b**) respectively using potassium persulfate under acidic conditions.

General procedures for the synthesis of 2,4,5-trisubstituted imidazoles.

Unless otherwise stated, the procedures for the synthesis of the 2,4,5-trisubstituted imidazoles are as follows:

Method A

To a solution of the 1,2-dione (1 equiv) in glacial acetic acid was added NH_4OAc (10 equiv) followed by aldehyde (1.1 - 1.3 equiv). The reaction mixture was then heated to 115 °C in an oil bath and left to stir overnight. After the reaction was cooled to room temperature, the pH of the reaction mixture was adjusted to 8 with saturated NaHCO_3 solution and solid NaHCO_3 and extracted with ethyl acetate. The organic extracts were dried over anhydrous Na_2SO_4 , filtered and the solvent was removed *in vacuo* to give the crude product which was purified by silica gel chromatography to afford the final product.

Method B

To a solution of the 1,2-dione (1 equiv) in glacial acetic acid was added NH_4OAc (10 equiv), aldehyde (1.1 - 1.3 equiv) and $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (0.3 – 2.0 equiv). The reaction mixture was then heated to 80 °C in an oil bath and left to stir overnight. After the reaction was cooled to room temperature, the pH of the reaction mixture was adjusted to 8 with saturated NaHCO_3 solution and solid NaHCO_3 and extracted with ethyl acetate. The organic extracts were dried over anhydrous Na_2SO_4 , filtered and the solvent was removed *in vacuo* to give the crude product which was purified by silica gel chromatography to afford the final product.

The following compounds have been synthesized accordingly:

4-(2-(2,6-difluorophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl)pyridine (1a, IM-31, TA-01)

Synthesized according to general procedure A using **9** and 2,6-difluorobenzaldehyde. **1a** was obtained as a white solid in 97% yield (74 mg). ^1H NMR (400 MHz, $\text{CD}_3\text{OD}/\text{DMSO}-d_6$ 3: 1): δ = 8.51 (d, J = 6.1 Hz, 2H), 7.66 – 7.56 (m, 5H), 7.31 – 7.23 (m, 4H); HRMS-ESI m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{13}\text{F}_3\text{N}_3$: 352.1056, found: 352.1065.

4-(2-(2-fluorophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl)pyridine (1b, IM-30, TA-02)

Synthesized according to general procedure A using **9** and 2-fluorobenzaldehyde. **1b** was obtained as an off-white solid in 68% yield (36 mg). ^1H NMR (400 MHz, $\text{CD}_3\text{OD}/\text{DMSO}-d_6$ 4: 1): δ = 8.48 (d, J = 4.4 Hz, 2H), 8.06 (td, J = 7.6, 1.5 Hz, 1H), 7.60 – 7.57 (m, 4H), 7.55 – 7.51 (m, 1H), 7.40 – 7.32 (m, 2H), 7.26 (t, J = 8.7 Hz, 2H); HRMS-ESI m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{14}\text{F}_2\text{N}_3$: 334.1150, found: 334.1156.

4-(2-(1-fluoronaphthalen-2-yl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl)pyridine (1c, IM-29)

Synthesized according to general procedure A using **9** and 1-fluoro-2-naphthaldehyde. **1c** was obtained as an off-white solid in 56% yield (50 mg). ¹H NMR (400 MHz, DMSO-d₆/CD₃OD 4:1): δ = 8.50 (d, *J* = 5.7 Hz, 2H), 8.18 – 8.12 (m, 2H), 8.03 (d, *J* = 8.0 Hz, 1H), 7.88 (d, *J* = 8.7 Hz, 1H), 7.71 – 7.64 (m, 2H), 7.60 (dd, *J* = 8.8, 5.5 Hz, 2H), 7.50 (dd, *J* = 4.6, 1.6 Hz, 2H), 7.30 (t, *J* = 8.7 Hz, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₄H₁₆F₂N₃: 384.1307, found: 384.1313.

4-(2-(naphthalen-2-yl)-4(5)-(m-tolyl)-1H-imidazol-5(4)-yl)pyridine (2f, IM-01)

Synthesized according to general procedure B using **10a** and 2-naphthaldehyde. **2f** was obtained as a pale yellow solid in 49% yield (39 mg). ¹H NMR (400 MHz, DMSO-d₆): δ = 13.08 (s, 1H), 8.63 (s, 1H), 8.48 (s, 2H), 8.26 (dd, *J* = 8.6, 1.7 Hz, 1H), 8.03 (d, *J* = 8.7 Hz, 1H), 8.00 – 7.90 (m, 2H), 7.62 – 7.50 (m, 4H), 7.49 – 7.21 (m, 4H), 2.38 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₅H₂₀N₃: 362.16517, found: 362.16574.

4-(2-(4-(methylsulfonyl)phenyl)-4(5)-(m-tolyl)-1H-imidazol-5(4)-yl)pyridine (2g, IM-33)

Synthesized according to general procedure A using **10a** and 4-(methylsulfonyl)benzaldehyde. **2g** was obtained as a light-yellow solid in 45% yield (43 mg). ¹H NMR (400 MHz, CD₃OD): δ = 8.40 (s, 2H), 8.23 (d, *J* = 8 Hz, 2H), 8.04 (d, *J* = 8 Hz, 2H), 7.58 (d, *J* = 4 Hz, 2H), 7.35 – 7.27 (m, 4H), 3.17 (s, 3H), 2.37 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₂H₂₀N₃O₂S: 390.1271, found: 390.1269.

N-(4-(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)phenyl)methanesulfonamide (2h, IM-35)

Synthesized according to general procedure A using **10a** and *N*-(4-formylphenyl)methanesulfonamide. **2h** was obtained as a yellow solid in 52% yield (76.8 mg). ¹H NMR (400 MHz, DMSO-d₆): δ = 12.83 (s, br, 1H), 9.98 (s, br, 1H), 8.54 – 8.44 (m, 2H), 8.03 (d, *J* = 8.1 Hz, 2H), 7.49 (s, 2H), 7.38 (s, 2H), 7.31 – 7.29 (m, 4H), 3.06 (s, 3H), 2.37 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₂H₂₁N₄O₂S: 405.1380, found: 405.1383.

4-(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)benzonitrile (2i, IM-36)

Synthesized according to general procedure A using **10a** and 4-formylbenzonitrile. **2i** was obtained as a white solid in 80% yield (62 mg). ¹H NMR (400 MHz, CD₃OD): δ = 8.44 (d, *J* = 4 Hz, 2H), 8.19 (d, *J* = 8 Hz, 2H), 7.85 (d, *J* = 8 Hz, 2H), 7.60 (d, *J* = 4 Hz, 2H), 7.38 – 7.29 (m, 4H), 2.39 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₂H₁₇N₄: 337.1448, found: 337.1458.

(Z)-N'-hydroxy-4-(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)benzimidamide (2j, IM-37)

To a solution of **2i** (40 mg, 0.12 mmol, 1 equiv) in ethanol (10 mL) was added hydroxylamine hydrochloride (26 mg, 0.37 mmol, 3 equiv) and triethylamine (37 mg, 0.37 mmol, 3 equiv). The reaction mixture was heated to reflux at 95 °C and left to stir overnight. The solvent was removed *in vacuo* to give the crude product which was purified by silica gel column chromatography (petroleum ether/ethyl acetate/methanol 20:20:1) to afford **2j** as a light yellow solid in 61% yield (42 mg). ¹H NMR (400 MHz, CD₃OD): δ = 8.41 (s, 2H), 8.04 (d, *J* = 8 Hz, 2H), 7.78 (d, *J* = 8 Hz, 2H), 7.57 (d, *J* = 4 Hz, 2H), 7.36 – 7.26 (m, 4H), 2.38 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₂H₂₀N₅O: 370.1662, found: 370.1665.

4-(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)benzoic acid (2k, IM-38)

Synthesized according to general procedure A using **10a** and 4-formylbenzoic acid. **2k** was obtained as a light yellow solid in 45% yield (222 mg). ¹H NMR (400 MHz, CD₃OD): δ = 8.42 (s, *J* = 4 Hz, 2H), 8.07 (d, *J* = 8 Hz, 2H), 8.01 (d, *J* = 8 Hz, 2H), 7.59 (d, *J* = 4 Hz, 2H), 7.38 - 7.26 (m, 4H), 2.39 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₂H₁₈N₃O₂: 356.1394, found: 356.1399.

4-(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)benzamide (2l, IM-39)

Compound **2k** (36.5 mg, 0.10 mmol, 1 equiv) was dissolved in thionyl chloride (8 mL) and the reaction mixture was heated up to 80 °C and stirred for 3h. Thionyl chloride was removed *in vacuo*, the resulting residue was dissolved in dichloromethane (5 mL) and added dropwise to (28 – 30%) ammonium hydroxide solution (10 mL) at 0 °C and stirred for 30min during which the product precipitates out of solution. The crude product was collected by filtration and purification by silica gel column chromatography (dichloromethane/methanol 40:1) afforded **2l** as a yellow solid in 72% yield (25.5 mg). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 13.08 (s, br, 1H), 8.48 (s, 2H), 8.17 (d, *J* = 8 Hz, 2H), 8.04 (s, 1H), 7.99 (d, *J* = 8 Hz, 2H), 7.52 (d, *J* = 4 Hz, 2H), 7.41 - 7.27 (m, 5H), 2.36 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₂H₁₉N₄O: 355.1553, found: 355.1554.

Methyl 4-(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)benzoate (2m, IM-40)

Compound **2k** (40 mg, 0.11 mmol, 1 equiv) was dissolved in thionyl chloride (8 mL) and the reaction mixture was then heated up to 80 °C and stirred for 3h. Thionyl chloride was removed *in vacuo* and the resulting residue was dissolved in methanol (5 mL) and stirred for 30min at room temperature. Removal of solvent afforded the crude product which was purified by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **2m** as a yellow solid in 74% yield (30mg). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 8.48 (s, 2H), 8.23 (d, *J* = 8 Hz, 2H), 8.07 (d, *J* = 8 Hz, 2H), 7.52 (d, *J* = 4 Hz, 2H), 7.41 - 7.31 (m, 4H), 3.88 (s, 3H), 2.36 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₃H₂₀N₃O₂: 370.1550, found: 370.1552.

4-(2-(4-nitrophenyl)-4(5)-(m-tolyl)-1H-imidazol-5(4)-yl)pyridine (2n, IM-32)

Synthesized according to general procedure A using **10a** and 4-nitrobenzaldehyde. **2n** was obtained as a light yellow solid in 40% yield (35 mg). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 8.49 (s, 2H), 8.38 - 8.33 (m, 4H), 7.53 (s, 2H), 7.42 - 7.33 (m, 4H), 2.38 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₁H₁₇N₄O₂: 357.1346, found: 357.1347.

4-(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)aniline (2o, IM-34)

To a solution of **2n** (21 mg, 0.06 mmol, 1 equiv) in methanol was added 10% palladium on carbon (3.2 mg, 0.003 mmol, 0.05 equiv). Hydrogen gas was introduced into the solution via a balloon and the reaction mixture was stirred at room temperature for 12h. The reaction mixture was filtered over celite and methanol was removed *in vacuo* to give the crude product. Purification by silica gel column chromatography (petroleum ether/ethyl acetate 1:5) afforded **2o** as a yellow solid in 55% yield (10.8 mg). ¹H NMR (400 MHz, CD₃OD): δ = 8.39 (s, 2H),

7.74 (d, $J = 8$ Hz, 2H), 7.54 (d, $J = 4$ Hz, 2H), 7.34 - 7.23 (m, 4H), 6.78 (d, $J = 8$ Hz, 2H), 2.37 (s, 3H); **HRMS-ESI** m/z $[M+H]^+$ calcd for $C_{21}H_{19}N_4$: 327.1604, found: 327.1604.

4-(4(5)-(m-tolyl)-1H-imidazol-5(4)-yl)pyridine (2p, IM-44)

Compound **10a** (68 mg, 0.30 mmol, 1 equiv), 37% formaldehyde solution (25 μ L, 0.33 mmol, 1.1 equiv), NH_4OAc (231 mg, 3.0 mmol, 10 equiv) and glacial acetic acid (1.5 mL) were combined in a microwave reaction vial and sealed. The reaction mixture was then heated in a microwave reactor for 6min at 180 °C. After cooling, the reaction mixture was added dropwise to concentrated ammonium hydroxide solution at 0 °C. The yellow precipitate obtained was collected by filtration, washed with water, and dried to afford **2p** in 44% yield (31 mg) which was used without further purification. **^1H NMR** (400 MHz, CD_3OD): $\delta = 8.40$ (d, $J = 6.4$ Hz, 2H), 7.85 (s, 1H), 7.50 (d, $J = 5.6$ Hz, 2H), 7.32 - 7.22 (m, 4H), 2.36 (s, 3H); **HRMS-ESI** m/z $[M+H]^+$ calcd for $C_{15}H_{14}N_3$: 236.1182, found: 236.1190.

N,N-dimethyl-1-(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)methanamine (2q, IM-42)

To a solution of **2p** (52 mg, 0.22 mmol, 1 equiv) in ethanol was added 37% formaldehyde solution (19 μ L, 0.26 mmol, 1.2 equiv) and dimethylamine (29 mg, 0.89 mmol, 1.2 equiv). The reaction mixture was heated up to 70 °C and stirred for 15h. After cooling down to room temperature the solvent was removed *in vacuo* to give the crude product. Purification by silica gel column chromatography (dichloromethane/methanol 10:1) afforded **2q** as a light yellow solid in 64% yield (41 mg). **^1H NMR** (400 MHz, CD_3OD): $\delta = 8.40$ (s, 2H), 7.50 (s, 2H), 7.33 - 7.21 (m, 4H), 3.67 (s, 3H), 2.38 (s, 6H), 2.35 (s, 3H); **HRMS-ESI** m/z $[M+H]^+$ calcd for $C_{18}H_{21}N_4$: 293.1761, found: 293.1761.

4-(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)but-3-yn-1-ol (2r, IM-41)

Compound **2p** (180 mg, 0.77 mmol, 1 equiv) was dissolved in THF (5 mL) followed by the addition of *N*-iodosuccinimide (207 mg, 0.92 mmol, 1.2 equiv) in two portions at 30min intervals. The solution was allowed to stir at room temperature for another 3h in darkness. Upon completion, the reaction mixture was quenched with saturated $Na_2S_2O_3$ solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na_2SO_4 and filtered. Removal of the solvent *in vacuo* afforded the crude product which was purified by silica gel column chromatography (dichloromethane/methanol 10:1) to afford **11** as a yellow solid in 80% yield (226 mg).

Dry triethylamine (1.7 mL) was first degassed by bubbling N_2 through the solution for 15min. To this was added **11** (47 mg, 0.13 mmol, 1.0 equiv), $Pd(PPh_3)_4$ (7.5 mg, 0.0065 mmol, 0.05 equiv), CuI (2.5 mg, 0.013 mmol, 0.1 equiv), and 3-butyne-1-ol (11 mg, 0.16 mmol, 1.2 equiv) in this order under N_2 . The solution was then stirred at room temperature for 6h. Upon reaction completion, triethylamine was removed *in vacuo* and the residue obtained was dissolved in ethyl acetate and filtered through celite. The filtrate was washed with brine and the organic extracts were dried over anhydrous Na_2SO_4 and filtered. Removal of the solvent *in vacuo* afforded the crude product which was purified by silica gel column chromatography (dichloromethane/methanol 100:5) to afford **2r** as a yellow oil in 37% yield (15 mg). **^1H NMR**

(400 MHz, CD₃OD): δ = 8.58 (d, J = 4 Hz, 2H), 8.03 (d, J = 8 Hz, 2H), 7.45 – 7.36 (m, 3H), 7.31 (d, J = 7.3 Hz, 1H), 3.78 (t, J = 8 Hz, 2H), 2.71 (t, J = 8 Hz, 2H), 2.41 (s, 3H); **HRMS-ESI** m/z [M+H]⁺ calcd for C₁₉H₁₈N₃O: 304.1444, found: 304.1444.

Cyclohex-1-en-1-yl(5(4)-(pyridin-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)methanol (2s, IM-43)

To a solution of **2p** (50 mg, 0.21 mmol, 1 equiv) in dichloromethane (5 mL) was added triethylamine (43 mg, 0.42 mmol, 2 equiv) and triphenylmethyl chloride (59 mg, 0.21 mmol, 1 equiv). The reaction mixture was allowed to stir at room temperature for 12h. Upon completion water was added to quench the reaction and extracted with dichloromethane. The combined organic extracts were washed with brine and dried over anhydrous Na₂SO₄. After filtration, the solvent was removed *in vacuo* to give the crude product. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **12** as a white solid in 85% yield (86 mg).

To a solution of **12** (40 mg, 0.084 mmol, 1 equiv) in anhydrous THF was added a solution of *n*-BuLi (1.15M in hexanes, 100 μ L, 0.12 mmol, 1.2 equiv) at 0 °C under N₂. The reaction mixture was allowed to warm up to room temperature and stirred for 30min after which it was cooled down again to 0 °C and 1-cyclohexene-1-carboxaldehyde (11 mg, 0.1 mmol, 1.2 equiv) was added. The reaction mixture was allowed to warm up to room temperature again and stirred for another 6h. Upon completion, the reaction mixture was diluted with ethyl acetate and washed with brine. Removal of the solvent *in vacuo* gave the crude product which was purified by silica gel column chromatography (dichloromethane/methanol 20:1) to afford **13** as a pale yellow oil containing a 1.4:1 mixture of atropisomers in 60% combined yield (29 mg).

To a solution of **13** (40 mg, 0.07 mmol, 1 equiv) in THF (2 mL) was added trifluoroacetic acid (23 mg, 0.2 mmol, 3 equiv) and deionized water (8 mg, 0.42 mmol, 6 equiv). The reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was then diluted with ethyl acetate and washed with brine. Removal of the solvent *in vacuo* gave the crude product which was purified by silica gel column chromatography (dichloromethane/methanol 60:1) to afford **2s** as a pale yellow oil in 80% yield (19 mg). **¹H NMR** (400 MHz, CDCl₃): δ = 8.46 (d, J = 4.8 Hz, 2H), 7.49 (d, J = 4.4 Hz, 2H), 7.32 - 7.20 (m, 4H), 5.95 (s, 1H), 5.28 (s, 1H), 2.37 (s, 3H), 2.17 (s, 4H), 1.91 - 1.57 (m, 4H) **HRMS-ESI** m/z [M+H]⁺ calcd for C₂₂H₂₄N₃O: 346.1914, found: 346.1914.

4-(2-(1-fluoronaphthalen-2-yl)-4(5)-(3-(trifluoromethyl)phenyl)-1H-imidazol-5(4)-yl)pyridine (2t, IM-02)

Synthesized according to general procedure B using **10b** and 1-fluoro-2-naphthaldehyde. **2t** was obtained as a pale yellow solid in 32% yield (32 mg). **¹H NMR** (400 MHz, CDCl₃): δ = 10.21 (s, 1H, NH), 8.67 (s, br, 1H), 8.44 (dd, J = 11.1, 5.2 Hz, 1H), 8.20 – 8.13 (m, 2H), 7.90 (d, J = 7.5 Hz, 1H), 7.84 – 7.36 (m, 9H); **HRMS-ESI** m/z [M+H]⁺ calcd for C₂₅H₁₆F₄N₃: 434.12749, found: 434.12802.

2-(2,6-difluorophenyl)-5(4)-(3,6-dihydro-2H-pyran-4-yl)-4(5)-(4-fluorophenyl)-1H-imidazole (3b, IM-23)

Synthesized according to general procedure A using **14a** and 2,6-difluorobenzaldehyde. **3b** was obtained as a pale yellow solid in 55% yield (31 mg). ¹H NMR (400 MHz, CD₃OD): δ = 7.58 (dd, *J* = 8.4, 5.5 Hz, 2H), 7.55 – 7.47 (m, 1H), 7.16 – 7.09 (m, 4H), 5.98 (s, 1H), 4.23 (d, *J* = 2.6 Hz, 2H), 3.84 (t, *J* = 5.4 Hz, 2H), 2.35 (s, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₀H₁₆F₃N₂O: 357.1209, found: 357.1208.

4-(5(4)-(3,6-dihydro-2H-pyran-4-yl)-4(5)-(4-fluorophenyl)-1H-imidazol-2-yl)phenol (3c, IM-24)

Synthesized according to general procedure B using **14a** and 4-hydroxybenzaldehyde. **3c** was obtained as an off-white solid in 63% yield (50 mg). ¹H NMR (400 MHz, CD₃OD): δ = 7.75 (d, *J* = 8.9 Hz, 2H), 7.57 (dd, *J* = 8.9, 5.4 Hz, 2H), 7.13 (t, *J* = 8.9 Hz, 2H), 6.86 (d, *J* = 8.9 Hz, 2H), 6.08 – 5.82 (m, 1H), 4.24 (q, *J* = 2.8 Hz, 2H), 3.84 (t, *J* = 5.4 Hz, 2H), 2.32 (td, *J* = 5.2, 2.6 Hz, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₀H₁₈FN₂O₂: 337.1347, found: 337.1345.

5(4)-(3,6-dihydro-2H-pyran-4-yl)-2-(2-fluorophenyl)-4(5)-(4-fluorophenyl)-1H-imidazole (3d, IM-20)

Synthesized according to general procedure B using **14a** and 2-fluorobenzaldehyde. **3d** was obtained as an off-white solid in 46% yield (25 mg). ¹H NMR (400 MHz, CD₃OD): δ = 7.91 (td, *J* = 7.6, 1.6 Hz, 1H), 7.60 – 7.57 (m, 2H), 7.47 – 7.41 (m, 1H), 7.31 – 7.23 (m, 2H), 7.14 (t, *J* = 8.4 Hz, 2H), 5.98 (s, 1H), 4.23 (d, *J* = 2 Hz, 2H), 3.84 (t, *J* = 5.2 Hz, 2H), 2.34 (s, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₀H₁₇F₂N₂O: 339.1303, found: 339.1300.

5(4)-(3,6-dihydro-2H-pyran-4-yl)-2-(1-fluoronaphthalen-2-yl)-4(5)-(4-fluorophenyl)-1H-imidazole (3e, IM-22)

Synthesized according to general procedure A using **14a** and 1-fluoro-2-naphthaldehyde. **3e** was obtained as a pale yellow solid in 90% yield (49 mg). ¹H NMR (400 MHz, CD₃OD): δ = 8.17 – 8.15 (m, 1H), 7.98 (dd, *J* = 8.6, 7.4 Hz, 1H), 7.93 – 7.91 (m, 1H), 7.75 (d, *J* = 8.7 Hz, 1H), 7.62 – 7.56 (m, 4H), 7.14 (t, *J* = 8.7 Hz, 2H), 6.00 (s, 1H), 4.24 (d, *J* = 2.2 Hz, 2H), 3.85 (t, *J* = 5.4 Hz, 2H), 2.36 (s, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₄H₁₉F₂N₂O: 389.1460, found: 389.1455.

5(4)-(3,6-dihydro-2H-pyran-4-yl)-2-(2-fluorophenyl)-4(5)-(p-tolyl)-1H-imidazole (3f, IM-21)

To a solution of 1-ethynyl-4-methylbenzene (460 mg, 4 mmol, 2 equiv) in dry THF (8 mL) at room temperature was added a solution of *n*-BuLi (4 mmol, 2 equiv) in hexanes (2.4 M) dropwise while stirring. The solution was stirred for an additional 5min after which anhydrous LiBr (695 mg, 8 mmol, 4 equiv) was added and the mixture was stirred at room temperature for a further 30min. Following which, the mixture was cooled to -78 °C and transferred dropwise to a pre-cooled solution of tetrahydro-4H-pyran-4-one (200 mg, 2 mmol, 1 equiv) in dry THF (6 mL) at -78 °C. The cooling bath was then removed and the reaction was allowed to warm up to room temperature. Stirring was continued for another 40min after which the reaction was diluted with diethyl ether, washed with saturated NH₄Cl solution and dried over anhydrous

Na₂SO₄. Removal of the solvent *in vacuo* gave the crude product which was purified by silica gel column chromatography to give 4-(*p*-tolylethynyl)tetrahydro-2*H*-pyran-4-ol as a white solid in quantitative yield (580 mg).

A solution of 4-(*p*-tolylethynyl)tetrahydro-2*H*-pyran-4-ol (550 mg, 2.5 mmol, 1 equiv) in a 6:1 mixture of 1,4-dioxane/H₂O was cooled to 0 °C. KMnO₄ (1.6 g, 10.2 mmol, 4 equiv) was then added portionwise and the reaction was stirred at 0 °C for 5min after which the ice bath was removed and the reaction stirred at room temperature. The reaction was monitored by TLC every 5min and when TLC indicated the disappearance of the starting alkyne, the reaction was quenched with saturated NaHSO₃ solution at 0 °C. The reaction was extracted with ethyl acetate and the organic extracts dried with anhydrous Na₂SO₄. Removal of the solvent *in vacuo* gave the crude product which was purified by silica gel column chromatography to give **14b** as a yellow viscous liquid in 52% yield (320 mg).

Compound **3f** was synthesized according to general procedure A using **14b** and 2-fluorobenzaldehyde. **3f** was obtained as an off-white solid in 79% yield. ¹H NMR (400 MHz, CD₃OD): δ = 7.90 (td, *J* = 7.6, 2 Hz, 1H), 7.45-7.39 (m, 3H), 7.29-7.25 (m, 1H), 7.25-7.20 (m, 3H), 5.97 (m, 1H), 4.22 (dd, *J* = 5.6, 2.8 Hz, 2H), 3.81 (t, *J* = 5.2 Hz, 2H), 2.35 (s, 3H), 2.33 (m, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₁H₂₀FN₂O: 335.1554, found: 335.1555.

2-(2,6-difluorophenyl)-5(4)-(3,6-dihydro-2*H*-pyran-4-yl)-4(5)-(m-tolyl)-1*H*-imidazole (4b, IM-18)

Synthesized according to general procedure B using **15** and 2,6-difluorobenzaldehyde. **4b** was obtained as an off-white solid in 52% yield (60 mg). ¹H NMR (400 MHz, CDCl₃): δ = 9.65 (s, 1H), 7.52-7.41 (m, 1H), 7.33-7.26 (m, 3H), 7.16-7.11 (m, 1H), 7.05-6.98 (m, 2H), 6.09 (m, 1H), 4.26 (s, 2H), 3.83 (t, *J* = 5.6 Hz, 2H), 2.43 (m, 2H), 2.39 (s, 3H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₁H₁₉F₂N₂O: 353.1460, found: 353.1456.

2-(2-bromophenyl)-5(4)-(3,6-dihydro-2*H*-pyran-4-yl)-4(5)-(m-tolyl)-1*H*-imidazole (4c, IM-13)

Synthesized according to general procedure A using **15** and 2-bromobenzaldehyde. **4c** was obtained as an off-white solid in 84% yield (105 mg). ¹H NMR (400 MHz, CD₃OD): δ = 7.73 (dd, *J* = 8, 0.8 Hz, 1H), 7.62 (dd, *J* = 7.6, 2 Hz, 1H), 7.46 (td, *J* = 7.2, 1.2 Hz, 1H), 7.40 (s, 1H), 7.38 – 7.34 (m, 2H), 7.28 (t, *J* = 7.6 Hz, 1H), 7.14 (d, *J* = 7.6 Hz, 1H), 5.99 (m, 1H), 4.24 (dd, *J* = 5.6, 2.8 Hz, 2H), 3.83 (t, *J* = 5.6 Hz, 2H), 2.37 (s, 3H), 2.36 (m, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₁H₂₀BrN₂O: 395.0754, found: 395.0751.

5(4)-(3,6-dihydro-2*H*-pyran-4-yl)-2-(4-nitrophenyl)-4(5)-(m-tolyl)-1*H*-imidazole (4d, IM-17)

Synthesized according to general procedure A using **15** and 4-nitrobenzaldehyde. **4d** was obtained as an orange solid in 54% yield (92 mg). ¹H NMR (400 MHz, CD₃OD): δ = 8.27 (d, *J* = 8.8 Hz, 2H), 8.10 (d, *J* = 8.8 Hz, 2H), 7.41 (s, 1H), 7.36 (d, *J* = 7.6 Hz, 1H), 7.30 (t, *J* = 7.2 Hz, 1H), 7.17 (d, *J* = 6.8 Hz, 1H), 6.02 (s, 1H), 4.25 (s, 2H), 3.83 (t, *J* = 5.2 Hz, 2H), 2.39 (s, 3H), 2.34 (s, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₁H₂₀N₃O₃: 362.1499, found: 362.1510.

4-(5(4)-(3,6-dihydro-2H-pyran-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)phenol (4e, IM-15)

Synthesized according to general procedure A using **15** and 4-hydroxybenzaldehyde. **4e** was obtained as an off-white solid in 74% yield (28 mg). ¹H NMR (400 MHz, CD₃OD): δ = 7.76 (d, *J* = 8.8 Hz, 2H), 7.38 (s, 1H), 7.33 (d, *J* = 8 Hz, 1H), 7.26 (t, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 7.2 Hz, 1H), 6.86 (d, *J* = 8.4 Hz, 2H), 5.97 (m, 1H), 4.24 (dd, *J* = 5.6, 2.8 Hz, 2H), 3.82 (t, *J* = 5.2 Hz, 2H), 2.37 (s, 3H), 2.32 (m, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₁H₂₁N₂O₂: 333.1598, found: 333.1613.

2-(2-chlorophenyl)-5(4)-(3,6-dihydro-2H-pyran-4-yl)-4(5)-(m-tolyl)-1H-imidazole (4f, IM-12)

Synthesized according to general procedure A using **15** and 2-chlorobenzaldehyde. **4f** was obtained as an off-white solid in 91% yield (100 mg). ¹H NMR (400 MHz, CD₃OD): δ = 7.70 – 7.67 (m, 1H), 7.55 – 7.53 (m, 1H), 7.45 – 7.39 (m, 3H), 7.36 (d, *J* = 7.6 Hz, 1H), 7.28 (t, *J* = 7.6 Hz, 1H), 7.14 (d, *J* = 7.6 Hz, 1H), 5.99 (s, 1H), 4.24 (d, *J* = 2.8 Hz, 2H), 3.83 (t, *J* = 5.2 Hz, 2H), 2.38 (s, 5H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₁H₂₀ClN₂O: 351.1259, found: 351.1270.

5(4)-(3,6-dihydro-2H-pyran-4-yl)-2-(2-fluorophenyl)-4(5)-(m-tolyl)-1H-imidazole (4g, IM-06)

Synthesized according to general procedure A using **15** and 2-fluorobenzaldehyde. **4g** was obtained as an off-white solid in 70% yield (66 mg). ¹H NMR (400 MHz, CDCl₃): δ = 9.62 (s, 1H), 8.34 (q, *J* = 8 Hz, 1H), 7.54 – 7.43 (m, 1H), 7.35 – 7.24 (m, 4H), 7.18 – 7.10 (m, 2H), 6.10 (s, 1H), 4.30 (s, 2H), 3.85 (t, *J* = 5.2 Hz, 2H), 2.40 (m, 5H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₁H₂₀FN₂O: 335.1554, found: 335.1572.

5(4)-(3,6-dihydro-2H-pyran-4-yl)-2-(1-fluoronaphthalen-2-yl)-4(5)-(m-tolyl)-1H-imidazole (4h, IM-03)

Synthesized according to general procedure A using **15** and 1-fluoro-2-naphthaldehyde. **4h** was obtained as a pale yellow solid in 45% yield (28 mg). ¹H NMR (400 MHz, CD₃OD): δ = 8.19 – 8.17 (m, 1H), 8.00 (dd, *J* = 8.6, 7.3 Hz, 1H), 7.94 (dt, *J* = 8.3, 1.9 Hz, 1H), 7.77 (d, *J* = 8.6 Hz, 1H), 7.65 – 7.56 (m, 2H), 7.44 (s, 1H), 7.39 (d, *J* = 7.7 Hz, 1H), 7.30 (t, *J* = 7.6 Hz, 1H), 7.16 (d, *J* = 7.5 Hz, 1H), 6.03 (s, 1H), 4.26 (d, *J* = 2.5 Hz, 2H), 3.85 (t, *J* = 5.4 Hz, 2H), 2.39 (m, 5H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₅H₂₂FN₂O: 385.1711, found: 385.1682.

5(4)-(3,6-dihydro-2H-pyran-4-yl)-2-phenyl-4(5)-(m-tolyl)-1H-imidazole (4i, IM-11)

Synthesized according to general procedure A using **15** and benzaldehyde. **4i** was obtained as an off-white solid in 67% yield (23 mg). ¹H NMR (400 MHz, CD₂Cl₂): δ = 7.90 – 7.88 (m, 2H), 7.44 – 7.40 (m, 3H), 7.37 – 7.33 (m, 2H), 7.26 (t, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 7.6 Hz, 1H), 6.00 (m, 1H), 4.23 (dd, *J* = 5.4, 2.7 Hz, 2H), 3.81 (t, *J* = 5.6 Hz, 2H), 2.37 (s, 3H), 2.33 (s, 2H); HRMS-ESI *m/z* [M+H]⁺ calcd for C₂₁H₂₁N₂O: 317.1648, found: 317.1663.

5(4)-(3,6-dihydro-2H-pyran-4-yl)-2-(6-methoxynaphthalen-2-yl)-4(5)-(m-tolyl)-1H-imidazole (4j, IM-09)

Synthesized according to general procedure A using **15** and 6-methoxy-2-naphthaldehyde. **4j** was obtained as an off-white solid in 92% yield (170 mg). ¹H NMR (400 MHz, CD₃OD): δ = 8.31 (s, 1H), 7.99 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.84 – 7.79 (m, 2H), 7.42 (s, 1H), 7.37 (d, *J* = 7.6 Hz, 1H), 7.29 (t, *J* = 7.2 Hz, 1H), 7.25 (d, *J* = 2 Hz, 1H), 7.17 – 7.15 (m, 2H), 6.02 (s, 1H), 4.26 (dd, *J* = 4.8, 2.4 Hz, 2H), 3.91 (s, 3H), 3.84 (t, *J* = 5.6 Hz, 2H), 2.39 (s, 3H), 2.35 (m, 2H); **HRMS-ESI** *m/z* [M+H]⁺ calcd for C₂₆H₂₅N₂O₂: 397.1911, found: 397.1913.

2-(5(4)-(3,6-dihydro-2H-pyran-4-yl)-4(5)-(m-tolyl)-1H-imidazol-2-yl)phenol (4k, IM-14)

Synthesized according to general procedure A using **15** and 2-hydroxybenzaldehyde. **4k** was obtained as an off-white solid in 97% yield (91 mg). ¹H NMR (400 MHz, CD₃OD): δ = 7.77 (dd, *J* = 7.6, 1.2 Hz, 1H), 7.40 (s, 1H), 7.36 (d, *J* = 8 H, 1H), 7.27 (t, *J* = 7.6 Hz, 1H), 7.21 (ddd, *J* = 8.4, 7.2, 1.6 Hz, 1H), 7.14 (d, *J* = 7.6 H, 1H), 6.94 (dd, *J* = 8.4, 1.2 Hz, 1H), 6.88 (ddd, *J* = 8, 7.2, 1.2 Hz, 1H), 6.01 (m, 1H), 4.23 (dd, *J* = 5.6, 2.8 Hz, 2H), 3.83 (t, *J* = 5.2 Hz, 2H), 2.37 (s, 3H), 2.36 (m, 2H); **HRMS-ESI** *m/z* [M+H]⁺ calcd for C₂₁H₂₁N₂O₂: 333.1598, found: 333.1610.

5-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-4-(pyridin-4-yl)oxazole (5b, OZ-12)

To a microwave vial containing a stirrer bar was added pivalic acid (17 mg, 0.2 mmol, 40 mol%), K₂CO₃ (170 mg, 1.3 mmol, 3 equiv), Pd(OAc)₂ (9 mg, 0.04 mmol, 10 mol%), 2-dicyclohexylphosphino-2',6'-diisopropoxy biphenyl (RuPhos, 39 mg, 0.08 mmol, 20 mol%) and **18b** (100 mg, 0.4 mmol, 1 equiv). The microwave vial was capped, evacuated and backfilled with argon three times. Dry, degassed toluene (2.1 mL) was added via syringe followed by 4-bromothioanisole (130 mg, 0.6 mmol, 1.5 equiv). The microwave vial was sealed with parafilm and heated in an oil bath at 115 °C overnight. After cooling, the reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was dried with anhydrous Na₂SO₄ and filtered. Removal of solvent *in vacuo* afforded the crude product which was purified by silica gel chromatography to give **19b** as an off-white solid in 90% yield (140 mg).

To a solution of **19b** (74 mg, 0.2 mmol, 1 equiv) in a mixture of glacial acetic acid (2.7 mL) and water (1.8 mL) was added K₂S₂O₈ (66 mg, 0.25 mmol, 1.2 equiv) at room temperature. The mixture was left to stir for 2 days at room temperature (44 hr). The reaction mixture was quenched with sat. NaHCO₃ and extracted with ethyl acetate. The combined organic phase was dried with anhydrous Na₂SO₄, and filtered. Removal of solvent *in vacuo* afforded the crude product. Purification by silica gel column chromatography (dichloromethane/methanol 100:3) afforded **5b** as a white solid in 85% yield (66 mg). ¹H NMR (400 MHz, CD₃OD) δ 8.57 (dd, *J* = 4.6, 1.6 Hz, 2H), 8.34 (d, *J* = 8.6 Hz, 2H), 7.88 (d, *J* = 8.6 Hz, 2H), 7.76 – 7.72 (m, 4H), 7.27 (t, *J* = 8.8 Hz, 2H), 2.87 (s, 3H); **HRMS-ESI** *m/z* [M+H]⁺ calcd for C₂₁H₁₆FN₂O₂S: 379.0911, found: 379.0911.

The following compounds have been additionally synthesized and found to be cardiogenic in the same way. These 2,4,5-trisubstituted azoles also promote cardiac differentiation across several embryonic and iPS cell lines, and also on microcarriers:

4-[4(5)-(4-fluorophenyl)-2-phenyl-1H-imidazol-5(4)-yl]pyridine (ZQX-14)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (20 mg, 0.1 mmol, 1 equiv), NH_4OAc (72 mg, 0.9 mmol 10 equiv), and benzaldehyde (12 mg, 0.11 mmol, 1.1 equiv) in glacial acetic acid (3 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-14** as a light yellow solid in 46% yield (13 mg). $R_f = 0.2$ (dichloromethane/methanol 20:1); mp: 232-233 °C decomposed; $^1\text{H NMR}$ (400 MHz, CD_3OD): δ 8.45 (s, 2H), 8.00 (d, $J = 8.8$ Hz, 2H), 7.54 (d, $J = 8.8$ Hz, 2H), 7.52-7.42 (m, 5H), 7.20 (apparent t, $J = 8.4$ Hz, 2H); $^{13}\text{C NMR}$ (100 MHz, CD_3OD): δ 164.39 (d, $J = 245.5$ Hz), 150.1, 149.3, 132.17 (d, $J = 8.4$ Hz), 130.9, 130.4, 130.0, 127.1, 123.4, 117.0, 116.78 (d, $J = 22$ Hz); **HRMS-ESI** m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{14}\text{FN}_3+\text{H}^+$: 316.1250, found: 316.1252. **HPLC purity**: >99%.

4-[2-(2,6-dichlorophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-15)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (23 mg, 0.1 mmol, 1 equiv), NH_4OAc (77.8 mg, 1 mmol 10 equiv), and 2,6-dichlorobenzaldehyde (19.3 mg, 0.11 mmol, 1.1 equiv) in glacial acetic acid (3 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-15** as a pale solid in 55% yield (21 mg). $R_f = 0.3$ (dichloromethane/methanol 20:1); mp: 258-260°C. $^1\text{H NMR}$ (400 MHz, CD_3OD): δ 8.45 (s, 2H), 7.67-7.50 (m, 7H), 7.21 (br s, 2H); $^{13}\text{C NMR}$ (100 MHz, CD_3OD): δ 164.39 (d, $J = 246$ Hz) 150.3, 137.8, 133.77 (d, $J = 3$ Hz), 133.3, 133.1, 133.0, 131.88 (d, $J = 9$ Hz), 130.8, 129.97 (d, $J = 12$ Hz), 129.4, 123.1, 117.05 (d, $J = 22$ Hz); **HRMS-ESI** m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{12}\text{Cl}_2\text{FN}_3+\text{H}^+$: 384.0471, found: 384.0481, **HPLC purity**: >96%.

4-[2-(2-methoxyphenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-16)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (32 mg, 0.14 mmol, 1 equiv), NH_4OAc (108.9 mg, 1.4 mmol 10 equiv), and 2-methoxybenzaldehyde (22 mg, 0.16 mmol, 1.1 equiv) in glacial acetic acid (3 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-16** as a pale solid in 62.5% yield (30 mg). $R_f = 0.2$ (dichloromethane/methanol 20:1); mp: 184-185°C; $^1\text{H NMR}$ (400 MHz, CD_3OD): δ 8.41 (s, 2H), 8.03 (d, $J = 9.2$ Hz, 1H), 7.53-7.49 (m, 4H), 7.45-7.41 (m, 1H), 7.21-7.15 (m, 3H), 7.10 (apparent t, $J = 7.6$ Hz 1H), 3.98 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CD_3OD) δ 164.36 (d, $J = 245.5$), 158.1, 150.1, 132.05 (d, $J = 30.1$ Hz), 130.5, 123.2, 122.0, 119.3, 116.83 (d, $J = 21.9$ Hz), 112.5, 56.2; **HRMS-ESI** m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{16}\text{FN}_3\text{O}+\text{H}^+$: 346.1356, found: 346.1363, **HPLC purity**: >96%.

4-[2-(2-chlorophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-17)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (23 mg, 0.1 mmol, 1 equiv), NH_4OAc (77.8 mg, 1 mmol 10 equiv), and 2-chlorobenzaldehyde (15.5 mg, 0.11 mmol, 1.1 equiv) in glacial acetic acid (3 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-17** as a white solid in 51%

yield (17.8mg). R_f = 0.2 (dichloromethane/methanol 20:1); mp: 220-221 °C. ^1H NMR (400 MHz, CD_3OD): δ 8.43 (d, J = 4.8Hz, 2H), 7.77-7.74 (m, 1H), 7.59-7.57 (m, 1H), 7.55-7.51 (m, 4H), 7.49-7.45 (m, 2H), 7.20 (apparent t, 2H); ^{13}C NMR (100 MHz, CD_3OD) δ =164.35 (d, J = 245.8 Hz), 150.2, 146.7, 134.1, 132.9, 132.1, 132.01 (d, J = 8.2 Hz), 131.3, 130.8, 128.3, 123.1, 116.97 (d, J = 21.9 Hz); HRMS-ESI m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{13}\text{ClFN}_3+\text{H}^+$: 350.0860, found: 350.0869, HPLC purity: >96%.

4-[2-(2,6-dimethoxyphenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine(ZQX-18)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (35 mg, 0.15 mmol, 1 equiv), NH_4OAc (116.7 mg, 1.5 mmol 10 equiv), and 2,6-dimethoxybenzaldehyde (28 mg, 0.17 mmol, 1.1 equiv) in glacial acetic acid (3 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-18** as a pale solid in 38% yield (21.4 mg). R_f = 0.2 (dichloromethane/methanol 20:1); mp: 199-200 °C decomposed. ^1H NMR (400 MHz, CD_3OD): δ 8.41 (s, 2H), 7.53-7.50 (m, 4H), 7.44 (t, J =8.4Hz, 1H), 7.18 (m, 2H), 6.77 (d, J =8.4Hz, 2H), 3.81 (s, 6H); ^{13}C NMR (100 MHz, CD_3OD) δ 164.19 (d, J = 245.2 Hz), 161.0, 151.0, 143.6, 132.8, 131.85 (d, J = 8.2Hz), 123.0, 116.84 (d, J = 21.8 Hz), 109.6, 105.0, 61.5, 56.4; HRMS-ESI m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{18}\text{FN}_3\text{O}_2+\text{H}^+$: 376.1461, found: 376.1473, HPLC purity: >96%.

4-[2-(2-chloro-6-fluorophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-19)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (40 mg, 0.18 mmol, 1 equiv), NH_4OAc (140.0 mg, 1.8 mmol 10 equiv), and 2-chloro-6-fluorobenzaldehyde (30 mg, 0.20 mmol, 1.1 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-19** as light yellow solid in 45% yield (30 mg). R_f = 0.2 (dichloromethane/methanol 20:1); mp: 274-276 °C. ^1H NMR (400 MHz, CD_3OD) δ 8.45 (s, 2H), 7.59-7.52 (m, 5H), 7.46 (d, J = 8.0 Hz, 1H), 7.32-7.27 (m, 1H), 7.21 (m, 2H); ^{13}C NMR (100 MHz, CD_3OD) δ 162.95 (d, J = 250 Hz), 150.3, 136.88 (d, J = 3 Hz), 133.51 (d, J = 9 Hz), 131.93 (d, J = 8 Hz), 126.92 (d, J = 4 Hz), 123.1, 120.2, 120.0, 117.0, 115.8, 115.6; HRMS-ESI m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{12}\text{ClF}_2\text{N}_3+\text{H}^+$: 368.0766, found: 368.0761, HPLC purity: >98%.

4-[2-(2-fluoro-6-methoxyphenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-20)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (40 mg, 0.18 mmol, 1 equiv), NH_4OAc (140.0 mg, 1.8 mmol 10 equiv), and 2-fluoro-6-methoxybenzaldehyde (30 mg, 0.20 mmol, 1.1 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-20** as light yellow solid in 38% yield (25 mg). R_f = 0.2 (dichloromethane/methanol 20:1); mp: 203-205 °C. ^1H NMR (400 MHz, CD_3OD) δ 8.42 (d, J = 4.9 Hz, 2H), 7.53-7.45 (m, 5H), 7.20 (br s, 2H), 6.98 (d, J = 8.5 Hz, 1H), 6.93-6.88 (t, J = 8.0 Hz, 1H), 3.88 (s, 3H); ^{13}C NMR (100 MHz, CD_3OD) δ

162.88 (d, $J = 246$ Hz), 160.8 (d, $J = 6$ Hz), 150.2, 133.04 (d, $J = 10$ Hz), 131.96 (d, $J = 8$ Hz), 123.1, 116.83, 109.2, 109.0, 108.20 (d, $J = 3$ Hz), 56.8. **HRMS-ESI** m/z $[M+H]^+$ calcd for $C_{21}H_{15}F_2N_3O+H^+$: 364.1261, found: 364.1256, **HPLC purity**: >97%.

4-[2-(2-bromo-6-fluorophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-21)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (40 mg, 0.18 mmol, 1 equiv), NH_4OAc (140.0 mg, 1.8 mmol 10 equiv), and 2-chloro-6-bromobenzaldehyde (43 mg, 0.20 mmol, 1.1 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-21** as light yellow solid in 37% yield (25 mg). $R_f = 0.2$ (dichloromethane/methanol 20:1); **mp**: 266-268°C. ^1H **NMR** (400 MHz, CD_3OD) δ 8.45 (d, $J = 4.6$ Hz, 2H), 7.66-7.59 (m, 1H), 7.59 – 7.44 (m, 5H), 7.37 – 7.30 (m, 1H), 7.21 (apparent t, $J = 8.7$ Hz, 2H); ^{13}C **NMR** (100 MHz, CD_3OD) δ 164.39 (d, $J = 245.9$ Hz), 162.89 (d, $J = 250.2$ Hz), 150.27, 142.16, 133.95 (d, $J = 9.2$ Hz), 131.91 (d, $J = 8.4$ Hz), 130.06 (d, $J = 3.6$ Hz), 126.15 (d, $J = 2.2$ Hz), 123.23, 122.04, 122.14 (d, $J = 18.4$ Hz), 117.03 (d, $J = 22.0$ Hz), 116.27, 116.04. **HRMS-ESI** m/z $[M+H]^+$ calcd for $C_{20}H_{12}BrF_2N_3+H^+$: 412.0261, found: 412.0246, **HPLC purity**: >95%.

4-[2-(2-bromophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-22)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (40 mg, 0.18 mmol, 1 equiv), NH_4OAc (140.0 mg, 1.8 mmol 10 equiv), and 2-bromobenzaldehyde (25ml, 0.20 mmol, 1.1 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-22** as white solid in 34% yield (24 mg). $R_f = 0.3$ (dichloromethane/methanol 20:1). **mp**: 198-200°C. ^1H **NMR** (400 MHz, CD_3OD) δ 8.44 (d, $J = 5.4$ Hz, 2H), 7.77 (dd, $J = 8.0, 1.1$ Hz, 1H), 7.69 (dd, $J = 7.6, 1.7$ Hz, 1H), 7.56-7.49 (m, 5H), 7.43-7.39 (m, 1H), 7.20 (apparent t, $J = 8.8$ Hz, 2H); ^{13}C **NMR** (100 MHz, CD_3OD) δ 164.36 (d, $J = 246$ Hz), 150.21, 148.04, 134.54, 133.08, 132.33, 132.02, 131.94, 128.77, 123.74, 123.13, 117.09, 116.87. **HRMS-ESI** m/z $[M+H]^+$ calcd for $C_{20}H_{13}BrFN_3+H^+$: 394.0355, found: 394.0340, **HPLC purity**: >96%.

4-[2-(2H-1,3-benzodioxol-5-yl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-23)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (40 mg, 0.18 mmol, 1 equiv), NH_4OAc (140.0 mg, 1.8 mmol 10 equiv), and piperonal (32mg, 0.20 mmol, 1.1 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-23** as yellow solid in 56% yield (35 mg). $R_f = 0.2$ (dichloromethane/methanol 20:1). **mp**: 260-262 °C. ^1H **NMR** (400 MHz, CD_3OD) δ 8.43 (d, $J = 5.1$ Hz, 2H), 7.54-7.49 (m, 4H), 7.20 (apparent t, $J = 8.7$ Hz, 2H), 6.94 (d, $J = 8.0$ Hz, 1H), 6.03 (s, 2H). ^{13}C **NMR** (100 MHz, $CDCl_3$) δ 164.01 (d, $J = 246$ Hz), 149.86, 149.38, 149.06, 131.76 (d, $J = 8.2$ Hz), 129.51, 124.58, 121.16, 116.73 (d, $J = 21$ Hz), 109.36, 107.24, 102.56.

HRMS-ESI m/z $[M+H]^+$ calcd for $C_{21}H_{14}FN_3O_2+H^+$: 360.1182, found: 360.1139, **HPLC purity**: >96%.

4-[2-(2-chloro-6-nitrophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-25)

Synthesized according to general method for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (40 mg, 0.18 mmol, 1 equiv), NH_4OAc (140.0 mg, 1.8 mmol 10 equiv), and 2-chloro-6-nitrobenzaldehyde (40 mg, 0.20 mmol, 1.1 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-25** as light yellow solid in 58% yield (40 mg). R_f = 0.2 (dichloromethane/methanol 20:1). **mp**: 268-270 °C. ^1H NMR (400 MHz, CD_3OD) δ 8.44 (s, 2H), 8.12 (dd, J = 8.2, 0.9 Hz, 1H), 7.97 (dd, J = 8.2, 0.9 Hz, 1H), 7.78 (t, J = 8.2 Hz, 1H), 7.56-7.50 (m, 4H), 7.24 – 7.18 (m, 2H); ^{13}C NMR (100 MHz, Acetone- D_6) δ 163.62 (d, J = 245 Hz), 152.47, 150.78, 140.39, 136.69, 134.81, 132.53, 131.52, 126.03, 123.92, 121.97, 116.77, 116.56. **HRMS-ESI** m/z $[M+H]^+$ calcd for $C_{20}H_{12}ClFN_4O_2+H^+$: 395.0711, found: 395.0720, **HPLC purity**: >97%.

2-[4(5)-(4-fluorophenyl)-5(4)-(pyridin-4-yl)-1H-imidazol-2-yl]-3,5-dimethoxyphenol (ZQX-26)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (40 mg, 0.18 mmol, 1 equiv), NH_4OAc (140.0 mg, 1.8 mmol 10 equiv), and 2-hydroxy-4,6-dimethoxybenzaldehyde (40mg, 0.20 mmol, 1.1 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-26** as yellow solid in 44% yield (30 mg). R_f = 0.2 (dichloromethane/methanol 20:1). **mp**: 204-206 °C. ^1H NMR (400 MHz, CD_3OD) δ 8.41 (d, J = 6.0 Hz, 2H), 7.56 – 7.53 (m, 2H), 7.51- 7.49(m, 2H), 7.22 (apparent t, J = 8.0 Hz, 2H), 6.21 (dd, J = 12.3, 2.3 Hz, 2H), 3.97 (s, 3H), 3.82 (s, 3H). ^{13}C NMR (100 MHz, CD_3OD) δ 164.47 (d, J = 245 Hz), 163.50, 161.76, 159.78, 150.13, 147.21, 132.37, 122.59, 117.03, 116.81, 97.03, 95.38, 91.17, 56.37, 55.86. **HRMS-ESI** m/z $[M+H]^+$ calcd for $C_{22}H_{18}FN_3O_3+H^+$: 392.1410, found: 392.1405, **HPLC purity**: >97%.

4-[4(5)-(4-fluorophenyl)-2-(2-nitrophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-27)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (100 mg, 0.44 mmol, 1 equiv), NH_4OAc (342.0 mg, 4.4 mmol 10 equiv), and 2-nitrobenzaldehyde (80 mg, 0.53 mmol, 1.2 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-27** as yellow solid in 34% yield (53.8 mg). R_f = 0.2 (dichloromethane/methanol 20:1). **mp**: 227-230 °C. ^1H NMR (400 MHz, CD_3OD) δ 8.43 (s, 2H), 8.09 (d, J = 8.1 Hz, 1H), 7.86 – 7.80 (m, 2H), 7.74 – 7.70 (m, 1H), 7.55 – 7.52 (m, 4H), 7.21 (apparent t, J = 8.3 Hz, 2H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.49 (d, J = 247 Hz), 149.30, 148.92, 144.03, 133.47, 132.22, 131.14, 131.06, 130.83, 125.50, 125.22, 122.32, 116.55, 116.33. **MS-ESI** m/z $[M+H]^+$ calcd for $C_{20}H_{13}FN_4O_2$: 360.1, found: 361.4, **HPLC purity**: >97%.

4-[2-(2,6-dimethylphenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-28)

Synthesized according to general A method for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (85 mg, 0.37 mmol, 1 equiv), NH_4OAc (288 mg, 3.7 mmol 10 equiv), and 2,6-dimethylbenzaldehyde (60 mg, 0.45 mmol, 1.2 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-28** as light red solid in 40.5% yield (50 mg). $R_f = 0.2$ (dichloromethane/methanol 20:1). **mp**: 285-287 °C. $^1\text{H NMR}$ (400 MHz, CD_3OD) δ 8.42 (d, $J = 8$ Hz, 2H), 7.56 – 7.52 (m, 4H), 7.31-7.27(m, 1H) 7.22-7.16 (m, 4H), 2.24 (s, 6H). $^{13}\text{C NMR}$ (100 MHz, CD_3OD) δ 164.25 (d, $J = 245\text{Hz}$), 150.23, 148.59, 143.46, 139.67, 131.82 (d, $J = 8.2$ Hz), 130.73, 128.51, 122.95, 116.98 (d, $J = 22\text{Hz}$), 20.21. **MS-ESI** m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{18}\text{FN}_3$: 343.2, found: 344.1, **HPLC purity**: >99%.

4-[4(5)-(4-fluorophenyl)-2-(2-methylphenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-29)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridine-4-yl)ethane-1,2-dione** (58 mg, 0.26 mmol, 1 equiv), NH_4OAc (202 mg, 2.6 mmol 10 equiv), and 2-methylbenzaldehyde (40 mg, 0.31 mmol, 1.2 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-29** as light yellow solid in 21% yield (18 mg). $R_f = 0.2$ (dichloromethane/methanol 20:1); **mp**: 218-219 °C. $^1\text{H NMR}$ (400 MHz, CD_3OD) δ 8.43 (s, 2H), 7.58–7.53 (m, 5H), 7.38 – 7.30 (m, 3H), 7.20 (apparent t, $J = 8.7$ Hz, 2H), 2.54 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CD_3OD) δ 164.32 (d, $J = 245$ Hz), 150.17, 149.62, 138.53, 132.03, 131.96, 131.18, 130.64 (d, $J = 11.2$ Hz), 126.99, 123.06, 116.94 (d, $J = 22$ Hz), 20.55. **MS-ESI** m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{16}\text{FN}_3$: 329.1, found: 330.4, **HPLC purity**: >97%.

4-[2-(2-fluoro-6-iodophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-30)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (64 mg, 0.28 mmol, 1 equiv), NH_4OAc (218 mg, 2.8 mmol 10 equiv), and 2-fluoro-6-iodobenzaldehyde (84 mg, 0.34 mmol, 1.2 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-30** as light yellow solid in 16% yield (20 mg). $R_f = 0.2$ (dichloromethane/methanol 20:1); **mp**: 250-253°C. $^1\text{H NMR}$ (400 MHz, $\text{CD}_3\text{OD}/\text{CDCl}_3$ 1:1) δ 8.40 (s, 2H), 7.78 – 7.76 (m, 1H), 7.54 – 7.47 (m, 4H), 7.22 – 7.17 (m, 2H), 7.11(apparent t, $J = 8$ Hz). $^{13}\text{C NMR}$ (100 MHz, CD_3OD) δ 163.26 (d, $J = 247$ Hz) 160.96 (d, $J = 252\text{Hz}$), 148.88, 143.31, 135.54 (d, $J = 3.6$ Hz), 133.03 (d, $J = 8.7$ Hz), 130.88 (d, $J = 8.2$ Hz), 124.95 (d, $J = 17.4$ Hz), 122.30, 116.40, 116.19, 116.12, 115.90, 99.81. **MS-ESI** m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{12}\text{F}_2\text{IN}_3$: 459.0, found: 460.2, **HPLC purity**: >97%.

4-[2-(2-aminophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-31)

To a solution of **ZQX-27** (30 mg, 0.08mol) in methanol and DCM (1:1, 5ml) was added palladium on charcoal (10%, 6mg) under the protection of N_2 . Hydrogen gas was introduced into the solution via a balloon and the reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was filtered over celite and methanol was removed *in vacuo* to give the crude product. Purification by silica gel column chromatography afforded **ZQX-31** as light yellow oil in 57% yield (15 mg). $R_f = 0.4$ (dichloromethane/methanol 20:1). $^1\text{H NMR}$ (400

MHz, CD₃OD/CDCl₃ 1:1) δ 8.32 (d, J = 6.2 Hz, 2H), 7.64 (d, J = 6.2 Hz, 2H), 7.57 (dd, J = 7.9, 1.2 Hz, 1H), 7.48 – 7.44 (m, 2H), 7.13 – 7.08 (m, 3H), 6.78 (d, J = 7.5 Hz, 1H), 6.71 – 6.67 (m, 1H). ¹³C NMR (100 MHz, CD₃OD/CDCl₃ 1:1) δ 163.46 (d, J = 248 Hz), 148.66, 146.36, 146.04, 131.24 (d, J = 8.3 Hz), 130.31, 126.84, 121.88, 117.57, 117.26, 116.45 (d, J = 21 Hz), 112.49. MS-ESI m/z [M+H]⁺ calcd for C₂₀H₁₅FN₄: 330.1, found: 331.4, HPLC purity: >97%.

4-[2-(2-methoxy-5-nitrophenyl)-4(5)-(4-fluorophenyl)-1H-imidazol-5(4)-yl]pyridine (ZQX-32)

Synthesized according to general method A for 2,4,5-trisubstituted imidazoles. A solution of **1-(4-fluorophenyl)-2-(pyridin-4-yl)ethane-1,2-dione** (40 mg, 0.17 mmol, 1 equiv), NH₄OAc (140 mg, 1.7 mmol 10 equiv), and 2-methoxyl-5-nitrobenzaldehyde (40 mg, 0.20 mmol, 1.2 equiv) in glacial acetic acid (5 mL) was stirred at 115°C overnight. Purification by silica gel column chromatography (dichloromethane/methanol 20:1) afforded **ZQX-32** as light yellow oil in 57% yield (38 mg). R_f = 0.3 (dichloromethane/methanol 20:1). ¹H NMR (400 MHz, CD₃OD) δ 9.01 (d, J = 2.8 Hz, 1H), 8.46 (s, 2H), 8.31 (dd, J = 9.2, 2.8 Hz, 1H), 7.78 (s, 2H), 7.56-7.53 (m, 3H), 7.28 (d, J = 9.2 Hz, 1H), 7.22 (apparent t, J = 8.6 Hz, 2H), 4.11 (s, 4H). ¹³C NMR (100 MHz, CD₃OD) δ 164.21 (d, J = 248 Hz) 161.91, 146.32, 144.29, 142.58, 131.96 (d, J = 8.4 Hz), 126.91, 125.81, 119.69, 117.03, 116.81, 112.64, 57.21. MS-ESI m/z [M+H]⁺ calcd for C₂₁H₁₅FN₄O₃: 390.1, found: 391.1; HPLC purity: >96%.

Known commercial compounds were used as shown in Table 1

[Table 1]


Compound	Company	Concentration used (μ M)	IC ₅₀ (published by companies)
BIRB 796 (Doramapimod)	Selleckchem	1-10	0.1 nM (p38 MAPK inhibition)
CHIR99021	R&D Systems (Tocris)	3	10 nM (p38 α MAPK inhibition) 6.7 nM (p38 β MAPK inhibition)
D4476	Cayman Chemical	5	200 nM (CK1 inhibition) 9.1 μ M (PKD1 inhibition) 5.8 μ M (p38 α MAPK inhibition)
IWP-2	Stemgent	5	27 nM (porcupine/Wnt inhibition)
SB202190	Sigma-Aldrich	5	50 nM (p38 α MAPK inhibition) 100 nM (p38 β MAPK inhibition)
SB203580	Sigma-Aldrich	1-10	0.3 - 0.5 μ M (p38 MAPK inhibition) 3 - 5 μ M (PKB phosphorylation)
SB431542	Sigma-Aldrich	5	94 nM (ALK5)
Skepinone-L	ShangHai Biochempartner	1-10	5 nM (p38-MAPK inhibition) 40 nM (TNF- α inhibition)
TAK 715	R&D Systems	5	7.1 nM (p38 α MAPK inhibition)
VX- 745	Selleckchem	1-10	10 nM (p38 α MAPK inhibition) 220 nM (p38 β MAPK inhibition)











Example 3: Kinase assay to determine IC₅₀ values against p38alpha mitogen-activated protein kinase (p38α MAPK), casein kinase 1 epsilon (CK1ε) and 1 delta (CK1δ)










The p38 MAPK IC₅₀ values of selected compounds except IM-32 to IM-44 were determined using the HitHunter™ p38 MAP kinase binding assay from DiscoverX Corporation (Fremont, CA, USA). The p38 MAPK IC₅₀ values of IM-32 to IM-44 and the CK1 IC₅₀ values of selected compounds were determined using LanthaScreen™ Eu kinase binding assay from Invitrogen (Life Technologies, Carlsbad, CA, USA). The assays were performed following the manufacturers' protocols in white 384-well plates (Cat. No. 3572; Corning Incorporated, Corning, NY, USA). SB203580 was used as the control in all assays. For the HitHunter™ p38 MAP kinase binding assay the compounds were dissolved in DMSO (5 mM stocks) and diluted to a final concentration of 2% (vol/vol) DMSO for all assays. Recombinant GST-tagged active p38α MAP kinase enzyme (Millipore, Billerica, MA, USA) was used for the HitHunter™ p38 MAP kinase binding assay. For the LanthaScreen™ Eu kinase binding assay the compounds were dissolved in DMSO (5 mM stocks) and diluted to a final concentration of 1% (vol/vol) DMSO for all assays. Each data point was done in triplicate. The assay was run using JANUS Automated Workstation according to the protocol developed using WinPREP software (Perkin Elmer Inc., Waltham, MA, USA). Tecan Infinite® M1000 microplate reader (Tecan Group Ltd., Männedorf, Switzerland) was used for luminescence measurements (HitHunter™ p38 MAP kinase binding assay) and fluorescence measurements (LanthaScreen™ Eu kinase binding assay; ex = 340 nm, em = 665, 615 nm). All data analysis was performed using GraphPad Prism 5 software (GraphPad Software Inc.). Inhibition curves and IC₅₀ values were generated by nonlinear regression analysis and data represent mean ± SEM.










Table 2 shows the structures of 2,4,5-tri-substituted azole compounds synthesized or obtained as mentioned in Example 2, (previously published compounds are indicated with *) and their IC₅₀ values against p38α MAPK, CK1δ, and CK1ε. The in vitro IC₅₀ values of the synthesized compounds against the relevant kinase targets are summarized. The IC₅₀ values were determined using either the HitHunter™ p38 MAPK binding assay from DiscoverX or the LanthaScreen™ Eu kinase binding assay (for p38alpha MAPK, CK1delta, and CK1epsilon) from Invitrogen.

[Table 2]





Compound	Structure	Concentration (μM)	p38α MAPK IC ₅₀ ± SEM (nM)	CK1δ IC ₅₀ ± SEM (nM)	CK1ε IC ₅₀ ± SEM (nM)
SB203580		1-10	24 ± 4	43 ± 2	63 ± 5

SB202190		5	24 ± 8	53 ± 7	83 ± 4
1a (IM-31)		0.5-5	6.7 ± 1.5	6.8 ± 0.9	6.4 ± 0.4
1b (IM-30)		1-10	20 ± 4	32 ± 4	32 ± 4
1c (IM-29)		5	73 ± 17	15 ± 3	16 ± 3
2a (IM-26)*		1-10	4.3 ± 1.7	78 ± 20	44 ± 5
2b (IM-19)*		0.5-10	4.7 ± 1.2	454 ± 28	150 ± 89
2c (IM-27)*		1-10	8.4 ± 3.0	1285 ± 828	411 ± 120
2d (IM-04)*		5	20 ± 7	490 ± 66	277 ± 40
2e (IM-28)*		1-10	24 ± 9	708 ± 43	274 ± 7
2f (IM-01)		5	98 ± 11	5% inhibition at 1 μ M	6% inhibition at 1 μ M

2g (IM-33)		5	9.5 ± 2.8	23% inhibition at 1 μ M	36% inhibition at 1 μ M
2h (IM-35)		5	5.0	13% inhibition at 1 μ M	40% inhibition at 1 μ M
2i (IM-36)		5	5.3 ± 0.5	11% inhibition at 1 μ M	36% inhibition at 1 μ M
2j (IM-37)		5	3.2 ± 0.3	889 ± 290	295 ± 48
2k (IM-38)		5	3.3 ± 1.1	4713 ± 1625	1061 ± 108
2l (IM-39)		5	2.7 ± 0.3	787 ± 98	300 ± 16
2m (IM-40)		5	3.7 ± 0.7	10% inhibition at 1 μ M	43% inhibition at 1 μ M
2n (IM-32)		5	4.4 ± 2.4	31% inhibition at 1 μ M	47% inhibition at 1 μ M
2o (IM-34)		5	2.8 ± 2.0	24% inhibition at 1 μ M	28% inhibition at 1 μ M

2p (IM-44)		5	45 ± 8	4% inhibition at 1 μM	42% inhibition at 1 μM
2q (IM-42)		5	26 ± 3	3% inhibition at 1 μM	29% inhibition at 1 μM
2r (IM-41)		5	47 ± 5	11% inhibition at 1 μM	38% inhibition at 1 μM
2s (IM-43)		5	11 ± 2	No inhibition at 1 μM	22% inhibition at 1 μM
2t (IM-02)		5	2655 ± 466	No inhibition at 1 μM	No inhibition at 1 μM
3a (IM-25)*		1-20	454 ± 67	1494 ± 285	5891 ± 180
3b (IM-23)		5	55 ± 14	548 ± 116	751 ± 168
3c (IM-24)		5	149 ± 33	14% inhibition at 1 μM	No inhibition at 1 μM
3d (IM-20)		5	561 ± 141	1523 ± 825	1145 ± 287
3e (IM-22)		5	2314 ± 714	14% inhibition at 1 μM	No inhibition at 1 μM

3f (IM-21)		5	3372 ± 824	No inhibition at 1 μM	No inhibition at 1 μM
4a (IM-16)*		1-10	73 ± 21	2539	5610 ± 319
4b (IM-18)		5	14 ± 2	3% inhibition at 1 μM	1235 ± 437
4c (IM-13)		5	19 ± 2	23% inhibition at 1 μM	23% inhibition at 1 μM
4d (IM-17)		5	20 ± 2	17% inhibition at 1 μM	No inhibition at 1 μM
4e (IM-15)		5	33 ± 2	No inhibition at 1 μM	No inhibition at 1 μM
4f (IM-12)		5	43 ± 2	23% inhibition at 1 μM	10% inhibition at 1 μM
4g (IM-06)		5	90 ± 20	3% inhibition at 1 μM	No inhibition at 1 μM
4h (IM-03)		5	262 ± 73	No inhibition at 1 μM	No inhibition at 1 μM
4i (IM-11)		5	526 ± 137	No inhibition at 1 μM	No inhibition at 1 μM

4j (IM-09)		5	2346 ± 374	13% inhibition at 1 μM	No inhibition at 1 μM
4k (IM-14)		5	> 5 μM	No inhibition at 1 μM	3% inhibition at 1 μM
5a (OZ-06)*		5	314 ± 44	46% inhibition at 1 μM	54% inhibition at 1 μM
5b (OZ-12)		5	>5 μM	34% inhibition at 1 μM	51% inhibition at 1 μM

Example 4: Differentiation of cardiomyocytes with 2,4,5-tri-substituted azole compounds

Initial studies with the 2,4,5-tri-substituted azole compounds were done at a fixed concentration of 5 μM. The 44 small molecules in table 2 were applied to hESC3 Nkx2.5^{GFP/w} cells after EB formation until day 8 of differentiation. On day 16 of differentiation, EBs were dissociated and analyzed with flow cytometry for green fluorescence protein (GFP) expression as a marker for cardiomyocyte differentiation. The results obtained are presented as GFP fold over DMSO control in Figure 6a, where 1 represents an effect similar to DMSO. Only compounds for which the GFP expression fold over DMSO exceeded 2 are significantly cardiogenic. The initial screen identified one novel compound (IM-30) with similar cardiogenic properties as SB203580 and SB202190, which are established compounds for cardiomyocyte differentiation. Interestingly, a highly similar compound, IM-31 showed complete inhibition of cardiomyocyte development. The reliability of GFP expression as a cardiomyocyte marker was confirmed by co-staining with cardiomyocyte antibodies such as troponin T (Figure 6b). The robustness of the differentiation protocol was demonstrated with an additional human embryonic stem cell line hESC7 (Figure 6c) and human induced pluripotent stem cells (hiPSC) (Figure 6d). Cyto-immunofluorescence staining of day 16 EBs derived from hiPSC, and grown on attachment plates showed characteristic cardio markers of typical cytoskeletal cardiac actin sarcomeres such as troponin T (cTnT), myosin light chain 2α (MLC2α) and sarcomeric actinin (SA). The mesoderm origin was confirmed with nuclear marker MEF2C (Figure 6e).

Cardiomyocyte differentiation was also repeated with a selection of small molecules at a concentration range of 0.5-20 μM (Figure 6f). The results showed that IM-31 can induce cardiomyocyte differentiation, when applied at a lower dose. Moreover, we showed that 1 μM of IM-31 has the same cardiogenic effect as 5 μM of SB203580 (Figure 6g). IM-31 can be

applied at a 5- times lower concentration than other comparable SB203580 analogues to induce cardiomyocyte differentiation. Therefore IM-31 is the most potent compound according to the invention.

Furthermore, a time course study of the differentiation process showed that the tested compounds can be applied either between days 1-8 or even more effectively between days 4-8 (Figure 6h). The example included 2,4,5-tri-substituted imidazoles (SB203580, D4476, IM-...) and thiazole (TAK715). The time course study revealed several false negative compounds such as IM-31, TAK715, and D4476 as they failed to induced cardiomyogenesis when applied at a concentration of 5 μ M between days 1-8 but were found to be good inducers when applied at the same concentration between days 4-8. A set time frame between days 4-8 allows a wider range of compounds to be tested without changing the concentration of the compounds. This is a great advantage, which will reduce the number of experiments to one concentration and one time course in order to investigate the correlations between a compound's *in vitro* effect on target protein(s) and its cardiomyogenic activity. Moreover the effect of 2,4,5-tri-substituted azoles on cardiomyogenesis in the days 4-8 time course indicates that late (post mesoderm) development of cardiomyocytes can be influenced with the method according to the invention.

Example 5: Correlation of CK1 IC₅₀ values with cardiomyocyte differentiation

Small molecules were tested for their inhibitory activities towards casein kinase 1 delta (CK1 δ) and 1 epsilon (CK1 ϵ). The *in vitro* LanthaScreen Eu kinase binding assay was used to determine the IC₅₀ values for 15 of the synthesized compounds and 5 commercial inhibitors including SB203580 (Table 3). Tested compounds displayed a wide range of affinity between 6.8 nM (high affinity = strong inhibition) to values over 1000 nM (low affinity = very weak inhibition). Further the list includes 2,4,5-tri-substituted azole of three classes, thiazole (TAK-715), oxazoles (OZ-06, OZ-12) and imidazoles (all other compounds). These selected compounds were used to differentiate hESC3 at fix doses of 5 μ M and they were applied during the differentiation process between days 4-8. All three classes of 2,4,5-tri-substituted azole are able to induce cardiac differentiation (Figure 7a). The Nkx2.5 GFP expression on day 11 was measured with flow cytometry and compared to the DMSO control. Values are expressed as fold over DMSO control (Figure 7a). Results from Figure 7a (CK1 ϵ/δ IC₅₀ values) and Figure 7b (GFP expression fold over DMSO) were plotted against each other in Figure 7b. A strong correlation between the CK1 δ/ϵ affinity and the differentiation results are shown with a log curve fit. We show here that CK1 inhibition correlates with cardiomyocyte differentiation.

Table 3 shows the differentiation of hESC3 into cardiomyocytes with 20 small molecules for which the CK1 IC₅₀ values were determined using a LanthaScreen Eu kinase binding assay.

[Table 3]

Compound	IC ₅₀ (nM)	
	CK1 δ	Ck1 ϵ
SB203580	43	63

SB202190	53	83
IM-4	490	277
IM-16	2539	5610
IM-19	454	150
IM-20	1523	1145
IM-23	548	751
IM-25	1494	5891
IM-26	78	44
IM-27	1285	411
IM-28	708	274
IM-29	15	16
IM-30	32	32
IM-31	6.8	6.4
IM-37	889	295
IM-38	4713	1061
IM-39	787	300
OZ-06		
OZ-12		
TAK-715	78	107
D4476	157	88
SB431542	174	147

Example 6: High Yield production of cardiomyocytes

To investigate if the yield of cardiomyocytes could be further improved, H3 hESCs Nkx2.5^{eGFP/w} were seeded at 2.5×10^6 cells/12-ULA well and treated with 3 μ M CHIR99021 for 24h. Thereafter the medium was changed and small molecules SB203580, IM-30 and IM-31 were added on two separate time courses, one from days 1-8 days and the other from days 4-8 at a concentration of 5 μ M. A known Wnt inhibitor, IWP-2, was also added on a time course from days 4-8 at the same concentration. The generated cardiomyocytes on day 11 were analyzed with flow cytometry and showed an average of 30% Nkx2.5 population for CHIR99021 only treatment and a 50% Nkx2.5 population when combined with small molecules (Figure 8a, left). The total cell count showed that the combination of CHIR99021 and IM-31 (applied at the late time course of days 4-8) has the greatest effect on cell expansion (2 fold increase, Figure 8a, center). The yield of cardiomyocytes shown in Figure 8a, right was calculated based on the following equation.

[Equation 1]

$$\text{yield} = \frac{\text{cell number day 11} * \text{cardiomyocyte (GFP) percentage day 11}}{\text{initial seeding number}}$$

The results showed that the use of CHIR99021 and IM-31 (4-8 days) gave the best cardiomyocyte yield on day 11 where almost 1.2 cardiomyocytes per hESC seeded was obtained (Figure 8a, right). The combination of IM-31 with CHIR99021 showed a twofold increase in cardiomyocyte yield when compared to other Wnt inhibitor compounds such as IWP-2. IWP-2








showed comparable Nkx2.5 expressions, but a strongly reduced cell growth (Figure 8a, center and 8a, right). IM-31 is not only a cardiac inducer, but it promotes cell growth at the same time.








The differentiated embryoid bodies were also visually analysed to determine cardiomyocyte functionality using parameters such as beat count (percentage of EBs which display contracting movements within 10s time frame), beating area (mm^2), and beat frequency (s^{-1} measured EB contraction within 10s time frame, Figure 8b). The functionality analyses shows similar results for CHIR99021 only treatment and CHIR99021 with SB203580 (days 1-8) or IM-31 (days 4-8) treatments. Under these treatments, beating counts were over 75% with $>5\text{mm}^2$ beating area and showed an average beating frequency of 25-30 beats per minute (0.5s^{-1}). However, the combination of CHIR99021 and IWP-2 displayed reduced functionality compared to the rest. IM-31 (days 1-8) showed inhibition of cardiomyocytes development which is in line with earlier observations that IM-31 applied at $5\text{ }\mu\text{M}$ between days 1-8 inhibit cardiomyogenesis. The results verify a high functionality of the generated cardiomyocytes.





Example 7: Alternative High Yield production of cardiomyocytes

Studies with the 2,4,5-tri-substituted azole compounds were done at a fixed concentration of $5\text{ }\mu\text{M}$ at an induction day 2 and alternatively at day 3. The small molecules in Table 4 (Structures and CK1 δ kinase affinities of the molecules also shown) were applied to hESC3 Nkx2.5^{eGFP/w} cells after 24h EB formation with $6\text{ }\mu\text{M}$ CHIR99021 until day 6 of differentiation. On day 14 of differentiation, EBs were visually analysed for cardiomyocyte differentiation. The green fluorescence protein (GFP) expression area (μm^2) was measured against the total embryoid body size (μm^2). The ratio of these measurements indicates the percentage of generated cardiomyocytes (Table 5). The initial screen identified novel compounds (TA-01, ZQX-19 and TA-02, ZQX-20) with higher cardiogenic properties as SB203580 and IWP-2, which are established compounds for cardiomyocyte differentiation at specific time course (Figure 9). The robustness of the differentiation protocol cardiac marker expression and cell growth was demonstrated with an additional human embryonic stem cell line H7 and 2 human induced pluripotent stem cells (IMR-90, Donor11) (Figure 10). Technology transfer of IM-31 (TA-01) from embryoid body differentiation to microcarrier platform differentiation is feasible and can produce same amounts of cardiomyocytes (cell numbers) when compared to IWP-2, which is an established compound for cardiomyocyte differentiation (Figure 11a, b and c).

[Table 4]

Name	Structure	MW	CK15
Zqx-32		390.1128	51.90
Zqx-31		330.1281	1753
Zqx-30		459.0044	25.64
Zqx-29		329.1328	46.06
Zqx-28		343.1485	25.58
Zqx-27		360.1203	14.19
Zqx-26		391.4024	4932

Zqx-25		394.7904	74.39
Zqx-23		359.3604	554.6
Zqx-22		394.2474	10.83
Zqx-21		412.2378	9.995
Zqx-20		363.3678	26.53
Zqx-19		367.7838	17.84
Zqx-18		375.4034	448.2

Zqx-17		349.7934	49.74
Zqx-16		345.3774	120.5
Zqx-15		384.2354	31.48
Zqx-14		315.3514	192.8

[Table 5]

Induction Day 2	Average GFP %	STD GFP %	Average GFP μm^2	STD GFP μm^2	Average Area μm^2	STD Area μm^2
ZQX-14	42.4%	8.3%	335.6	29.3	810.7	227.9
ZQX-15	0.0%	0.0%	0.0	0.0	129.4	18.6
ZQX-16	32.8%	4.8%	184.7	20.2	576.1	139.7
SB203580	34.6%	7.7%	217.8	41.8	655.4	230.2
Control (DMSO)	18.2%	10.6%	154.5	101.8	795.5	126.8
IWR-1	41.3%	14.0%	308.9	79.1	763.0	97.6
IWP-2	4.8%	4.1%	19.6	18.6	362.9	121.6
TA-01	1.5%	2.9%	19.1	38.2	814.7	423.6
TA-02	32.8%	10.2%	250.1	38.6	816.0	251.1
ZQX-17	30.4%	9.2%	183.0	73.8	586.7	114.5
ZQX-18	27.5%	18.7%	207.3	140.1	579.4	352.8
ZQX-19	2.4%	4.8%	46.4	92.7	903.3	733.4
ZQX-27	15.1%	13.5%	258.6	104.5	1469.4	672.9
ZQX-28	0.0%	0.0%	0.0	0.0	302.4	230.5
ZQX-29	28.6%	14.4%	277.1	120.3	876.4	829.7
ZQX-30	4.6%	5.3%	60.9	72.2	1361.8	335.4
ZQX-31	28.9%	6.6%	258.3	69.4	891.2	116.3
ZQX-32	32.8%	8.6%	157.6	41.7	483.6	58.9
ZQX-20	26.0%	6.5%	286.8	55.5	1145.3	348.1

ZQX-21	0.0%	0.0%	0.0	0.0	1383.8	109.6
ZQX-22	26.2%	7.6%	166.5	72.8	623.0	213.4
ZQX-25	0.0%	0.0%	0.0	0.0	544.3	51.2
ZQX-26	30.9%	5.4%	233.9	75.9	757.8	198.8
Induction Day 3	Average GFP %	STD GFP %	Average GFP μm^2	STD GFP μm^2	Average Area μm^2	STD Area μm^2
ZQX-27	3.4%	6.8%	57.9	115.7	1758.3	263.5
ZQX-28	2.1%	4.1%	6.1	12.1	271.7	30.9
ZQX-29	2.7%	5.4%	39.9	79.7	1296.6	182.9
ZQX-30	12.6%	10.6%	128.3	73.7	1142.4	334.3
ZQX-31	5.1%	6.2%	96.0	64.4	1662.3	472.0
ZQX-32	4.6%	4.3%	41.0	25.9	790.4	145.8
ZQX-20	37.3%	16.1%	331.1	21.8	996.2	390.2
ZQX-21	3.4%	6.7%	16.9	33.7	974.3	437.5
ZQX-22	24.4%	6.3%	284.4	84.9	1165.0	252.5
ZQX-25	15.6%	10.1%	163.6	105.0	1105.4	130.7
ZQX-26	8.3%	6.0%	88.2	48.7	1152.7	261.9
ZQX-14	5.9%	6.1%	91.6	94.9	1474.4	200.4
ZQX-15	0.0%	0.0%	0.0	0.0	384.0	208.7
ZQX-16	14.5%	5.8%	125.6	51.8	950.3	447.7
SB203580	3.7%	4.7%	40.2	35.4	814.2	236.5
Control (DMSO)	8.9%	6.7%	95.5	68.8	1088.6	46.4
IWR-1	51.1%	3.2%	426.3	46.6	831.4	77.6
IWP-2	38.4%	17.8%	216.9	38.3	604.5	180.6
TA-01	31.1%	1.0%	476.6	10.1	1529.1	82.8
TA-02	36.5%	6.9%	354.1	135.5	968.7	307.6
ZQX-17	24.6%	12.3%	232.7	134.4	971.6	535.9
ZQX-18	15.4%	15.5%	143.4	138.4	1065.1	213.1
ZQX-19	32.7%	7.1%	511.6	110.2	1616.9	446.8

Brief Description of Drawings

The accompanying drawings illustrate a disclosed embodiment and serves to explain the principles of the disclosed embodiment. It is to be understood, however, that the drawings are designed for purposes of illustration only, and not as a definition of the limits of the invention.

Fig. 1

[Fig. 1] shows the general structures of the 2,4,5-tri-substituted azole compounds synthesized.

Fig. 2

[Fig. 2] shows schematic synthesis route of imidazoles 1a – 1c as well as imidazoles ZQX-14-23 and ZQX-25-32.

Fig. 3

[Fig. 3] shows schematic synthesis route of imidazoles 2f – 2t.

Fig. 4

[Fig. 4] shows schematic synthesis route of imidazoles 3b – 3f and 4b – 4k.

Fig. 5

[Fig. 5] shows schematic synthesis route of oxazoles 5a and 5b.

Fig. 6a

[Fig. 6a] shows the hESCs differentiation with the 44 small molecules.

Fig. 6b

[Fig. 6b] shows the co-staining of green fluorescence protein expression and cardiac marker troponin T on hESC3.

Fig. 6c

[Fig. 6c] shows the differentiation of hESC7.

Fig. 6d

[Fig. 6d] shows the differentiation of human induced pluripotent stem cells.

Fig. 6e

[Fig. 6e] shows an IF staining of differentiated human induced pluripotent stem cells.

Fig. 6f

[Fig. 6f] shows hESC3 dose dependent differentiation with small molecules at different concentrations (μM).

Fig. 6g

[Fig. 6(g)] shows the Nkx2.5 expression of hESC3 treated with IM-31 (1 μM), IM-30 and SB203580 (5 μM).

Fig. 6h

[Fig. 6(h)] shows the hESC3 time course dependent differentiation with small molecules.

Fig. 7a and b

[Fig. 7a and b] show a correlation between CK1 inhibition and cardiomyogenesis.

Fig. 8a and b

[Fig. 8a and b] show a high efficiency in cardiomyocyte differentiation.

Fig. 9

[Fig. 9] in combination with Table 4 shows the time dependance of 2,4,5-tri-substituted azoles with CHIR99021 for cardiomyocyte differentiation.

Fig. 10

[Fig. 10] shows the stem cells robustness of high efficiency cardiomyocyte differentiation with 3 human induced pluripotent stem cells.

Fig. 11a, b and c

[Fig. 11a] shows the technical application of IM-31 (TA-01) on microcarrier platform technologies for large scale cardiac differentiation

[Fig. 11b] shows the stem cell pluripotency on microcarrier platform technologies prior to differentiation

[Fig. 11c] shows the cardiac differentiation efficiency of IM-31 (TA-01) on microcarrier platform technologies

Detailed Description of Drawings

Referring to Fig. 6, a detailed showing of the pluripotent stem cell differentiation into cardiomyocytes with small molecules is made. The drawings are explained in more detail: (a) Differentiation of hESC3 into cardiomyocytes with 44 compounds at 5 μ M applied between days 1-8 during differentiation. (b) Nkx2.5 green fluorescence protein (GFP) expression measured with flow cytometry and compared to DMSO control expressed as fold over DMSO. Representative flow cytometry analyses with GFP (green) and troponin T stain (red2) shows the absolute values of cardiac population. Process robustness was demonstrated with (c) hESC7 and (d) hiPSCs. (e) Cyto-immunofluorescence of differentiated cells shows structural segments of the cardiac sarcomeres with cTnT, MLC2a and sarcomeric actinin (SA), as well as nuclear mesoderm marker MEF2c on differentiated embryoid bodies. Nuclear stain is DAPI. (f) Titration of selected small molecules during the days 1-8 of the differentiation protocol shows concentration dependent GFP expression peaks, and identifies IM-31 as the strongest cardiomyocyte inducer. (g) Representative flow analyses of IM-31, IM-30 and SB203580 is shown in flow cytometer dot plot (h) Time course differentiation results with selected small compounds at 5 μ M induction for 24h, 0-3, 0-8 and 4-8 days illustrates late stage (post mesoderm) efficiency of small molecules. GFP was measured as fold over DMSO control in (a), (f), and (g).

Referring to Fig. 7, the drawings are explained in more detail: (a) compounds were dosed at 5 μ M during days 4-8 of the differentiation process. Green fluorescence protein (GFP) expression was measured with flow cytometry and compared to DMSO control showed in fold increase over DMSO. (b) IC₅₀ values for CK 1 delta and 1 epsilon from (Table 3) were plotted against the GFP expression fold (a), and a strong correlation was demonstrated.

Referring to Fig. 8a, the drawings are explained in more detail: (left) Differentiation of hESC3 into cardiomyocyte with 24h incubation of 3 μ M CHIR99021 followed by small molecules SB203580, IM-30, IM-31 and IWP-2 at 5 μ M delivered during days 1-8 and days 4-8 during a 11 day differentiation process. Green fluorescence protein (GFP) expression measured with flow cytometry is displayed in percentage over the whole population. (center) The viable cell number was measured on day 11 after EB dissociation with Nucleocounter. (right) The cardiomyocyte yields obtained with the small molecules combination protocol. The values were calculated using the flow cytometry data (left) and the cell count (center).

Referring to Fig. 8b, the drawings are explained in more detail: A Nikon Eclipse Ti microscope with an automated Time Resolved Video Analysis for cardiomyocyte contraction was used to calculate EB beating and frequency. Images show EBs in 12 Well plates after 16 days of differentiation. The percentage of beating EBs as well as the beating area was calculated with the analytical software and displayed in the table below the pictures. The beating contraction and frequency (s^{-1}) was analyzed from a sample of 16 EBs. Three representative images of a 10s time frame of contractile movement video analyses are shown in the lowest part of the figure.

Referring to Figure 9, the drawing shows the GFP are measurements of EBs after 14 days of differentiation with 2,4,5-tri-substituted azoles induced either on day 2 or day 3. Compounds groups (dark=day 3 high cardiac inducers; less dark, small= day 2high cardiac inducers; light colour= control and other commercial inhibitors for cardiac differentiation). The grey box means that there is no significant difference to control in this area of the graph.

Referring to Figure 10, the top part of the drawing shows the expression of cardiac markers (cTnt, MLC2a) of differentiated human embryonic stem cells (H7) and induced pluripotent stem cells (IMR-90, Donor 11) with CHIR99021 and IM-31 (TA-01) on day 14; and the lower part shows the cell count of differentiated human embryonic stem cells (H7) and induced pluripotent stem cells (IMR-90, Donor 11) with CHIR99021 and IM-31 (TA-01) on day 14.

Referring to Figure 11a of the drawing shows hPSC expanded on microcarriers and differentiated into beating cardiomyocytes aggregates (scale bar 500 μ M); left: HES-3 freshly seeded on microcarriers (100 μ m in diameter), center: hPSC expansion on microcarriers to embryoid bodies (500 μ m), right: cardiac differentiation with TA-01 on microcarriers to beating aggregates (> 1 mm). Fig. 11b shows pluripotency marker expression of hPSC on microcarriers during cell expansion, and Fig. 11c shows expression of cardiac markers (cTnt, MLC2a, MF20) of differentiated microcarrier-embryoid bodies with IM-31 (TA-01) and IWP-2 commercial wnt inhibitor for cardiac differentiation.

Industrial Applicability

The method and novel compounds as defined above may find multiple number of applications in which new ways for efficient stem cell differentiation are desirable. For example, the methods as defined above may be used to provide cardiomyocytes in higher


efficiency by using small molecules or combinations of small molecules at different differentiation stages. The invention, therefore, provides an improved method and new compounds to be used in such methods in order to generate cells that can be potentially used in regenerative medicine for treating heart diseases. It is of technological significance that higher cardiomyocyte yields can be achieved with small molecules according to the invention. Especially with the presented embryoid body based protocol in suspension culture the method of the invention may be scaled up for the production of cardiomyocytes with bioprocessing technologies to a magnitude of therapeutic significance.

It will be apparent that various other modifications and adaptations of the invention will be apparent to the person skilled in the art after reading the foregoing disclosure without departing from the spirit and scope of the invention and it is intended that all such modifications and adaptations come within the scope of the appended claims.


Claims

1. A method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (I) or (II) or a stereoisomer, tautomer, or a salt thereof

[Formula (I)]



[Formula (II)]




wherein R¹ represents fluorine substituted aryl having 6 to 10 carbon atoms, wherein the aryl is optionally additionally substituted by one or more substituents;

R² represents fluorine substituted phenyl, wherein the phenyl is optionally additionally substituted by one or more substituents;


R³ represents pyridinyl or pyran-4-yl; and

X represents NH.

2. The method according to claim 1, wherein the one or more substituents in R¹ is selected from amino, -COOH, hydroxyl, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxycarbonyl, chlorine, bromine, iodine, nitro or a -O- C₁-C₄-alkyl-O- bridge; and the one or more substituents in R² is selected from amino, -COOH, hydroxyl, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxycarbonyl, chlorine, bromine, iodine or nitro.
3. The method according to claim 1, wherein R³ represents pyridin-4-yl or 3,6-dihydro-2H-pyran-4-yl.
4. The method according to any of claims 1 to 3, wherein the compound of formula (I) is selected from the following compounds:



5. A method for inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocyte via casein kinase 1 inhibition said method comprising culturing the stem cells in the presence of a medium comprising a casein kinase 1 inhibitor of the formula (Ia) or a stereoisomer, tautomer, or a salt thereof



(Ia)


wherein B, B¹, Y¹ and Z¹ are absent or each independently selected from C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, thio-C₁-C₆-alkyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkenyl, five to six membered heterocycloalkyl, halo, -COOH, -CONH₂, C₁-C₆-carboxyl, halo-C₁-C₆-alkyl, halo-C₂-C₆-alkynyl, hydroxyl, C₁-C₆-alkoxy, thio-C₁-C₆-alkoxy, C₂-C₆-alkenyloxy, halo-C₁-C₆-alkoxy, halo-C₂-C₆-alkenyloxy, nitro, amino, N-hydroxy-imidamide, nitro-C₁-C₆-alkyl, nitro-C₂-C₆-alkenyl, nitro-C₂-C₆-alkynyl, five to six ring membered nitro-heterocyclyl, C₁-C₆-alkylamino, di-C₁-C₆-alkylamino, C₂-C₆-alkenylamine, C₂-C₆-alkynylamino, C₁-C₆-acyl, C₂-C₆-alkenoyl, C₂-C₆-alkynoyl, C₁-C₆-acylamino, di-C₁-C₆-acylamino, C₁-C₆-acyloxy, C₁-C₆-alkylsulfonyloxy, five to six ring membered heterocycloxy, five to six ring membered heterocycloamino, five to six ring membered haloheterocycloalkyl, C₁-C₆-alkylsulfinyl, C₁-C₆-alkylsulfonyl, C₁-C₆-alkylsulfonylamino, C₁-C₆-alkylcarbonyloxy, C₁-C₆-alkylthio, C₁-C₆-acylthio, phosphorus-containing groups such as phosphono and phosphinyl, aryl having 6 to 10 carbon atoms, five to six ring membered heteroaryl, C₁-C₄-alkylaryl having 6 or 10 carbon atoms in the aryl, five to six ring membered C₁-C₆-alkylheteroaryl, cyano, cyanate, isocyanate, -C(O)NH(C₁-C₆-alkyl), or -C(O)N(C₁-C₆-alkyl)₂ or two substituents forming an -O-C₂-C₆-alkyl-O- bridge,

Y is halo or nitro;


Z is halo or nitro;

provided that at least two of B, B¹, Y, Y¹, Z and Z¹ are not absent.

6. The method according to claim 5, wherein the compound of formula (Ia) is selected from the following compounds:




7. The method according to claim 5, wherein at least three of B, B¹, Y, Y¹, Z and Z¹ are not absent.
8. A method according to any of claims 1 to 7, wherein the casein kinase 1 inhibitor is added about 3 to 4 days after the mesoderm has been established.
9. A method according to any of claims 1 to 7, wherein the casein kinase inhibitor is added from about day 3 to 8 after the mesoderm has been established.
10. A method according to any of claims 1 to 7, wherein the casein kinase 1 inhibitor is present from day 3 to 8 of the differentiation.
11. A method according to any of claims 1 to 7, wherein the compound of formula (IV)
- [Formula (IV)]



is added to the embryoid bodies before the mesoderm has been established.

12. A method according to claim 11, wherein the incubation with the compound of formula (IV) lasts for about 24 hours.
13. A method according to claim 11 or 12, wherein the concentration of the casein kinase inhibitor is 0.5 to 20 μM and the concentration of the compound of formula (IV) is 2 to 20 μM .
14. The method according to claim 13, wherein the concentration of the casein kinase inhibitor is 0.5 to 5 μM .

15. A compound selected from the following compounds, or a stereoisomer, tautomer, or a salt thereof:



16. Compound as defined in claim 15 for use in inducing or enhancing the differentiation of pluripotent stem cells into cardiomyocytes *in vivo*.
17. Use of a compound of the formula (I) or (II) as defined in any one of claims 1 to 4, or a compound of the formula (Ia) as defined in claim 6, or a stereoisomer, tautomer, or a salt thereof, together with excipients, in the manufacture of a medicament for the treatment of heart diseases.

18. Use of a compound of the formula (I) or (II) as defined in any one of claims 1 to 4, or a compound of the formula (Ia) as defined in claim 6, or a stereoisomer, tautomer, or a salt thereof, together with excipients, in the manufacture of a kit for the treatment of heart diseases, wherein said kit comprises said compound and a label or instructions for the use thereof.
19. A kit for use in stem cell differentiation to cardiomyocytes *in vivo*, comprising a compound as defined in claim 15, or a stereoisomer, tautomer, or a salt thereof, together with excipients.